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A Tale Of Two Transgenes: Aav-Dystrophin And Aav-Spike Reveal Common
Themes For Gene Therapy And Vaccines
Abstract
Adeno-associated viruses (AAVs) are non-pathogenic, replication defective viruses that can facilitate
long-term gene transfer to a variety of tissues in vivo. However, the limited DNA packaging capacity of
AAV (~5 kb) poses challenges for the transfer of large genes. Additionally, while AAV is a minimally
immunogenic viral vector, the risk of potential immune response against exogenous, AAV-delivered
transgene products isn’t fully understood. Here I describe two in vivo AAV-mediated gene transfer projects
that utilize engineered, miniaturized versions of larger genes to overcome the AAV packaging capacity for
the disparate purposes of gene therapy for Duchenne muscular dystrophy and vaccination against SARSCoV-2. Duchenne muscular dystrophy (DMD) is a degenerative X-linked muscle disease caused by
mutations that result in the absence of the giant, rod-shaped structural protein dystrophin. While we have
previously demonstrated that systemic delivery of an AAV-deliverable miniaturized form of the dystrophin
paralog utrophin (AAV-⯑Utrophin) can complement for absence of dystrophin without the
immunogenicity observed against similarly designed AAV-⯑Dystrophin, we believe further improvements
can be made to the design of the miniaturized utrophin proteins to improve their functionality and
durability. Here we reconstructed the evolution of striated muscle as well as the piecemeal evolution of
the dystrophin gene. Based on this evolutionary reconstruction of dystrophin’s origin, we propose a
structural model for how the spectrin repeats within the rod domain of dystrophin and utrophin interact to
form a continuous, interlocking structure. Using this structural model of the dystrophin/utrophin rod
domain, we engineered a new AAV-deliverable utrophin protein (nano4-Utrophin) with a chimeric spectrin
repeat capable of maintaining tensile strength along the entire truncated rod domain. We then
demonstrate that following systemic administration using AAV9, nano4-Utrophin localizes to the
sarcolemma, restores sarcolemmal localization of ⯑-Sarcoglycan, and prevents ongoing muscle
regeneration in mdx mouse model of DMD. While this project utilized a paralogous protein approach to
avoid transgene product immunogenicity, my second project capitalizes on AAV-delivered exogenous
transgene immunogenicity. I demonstrate that a single intramuscular injection of AAV6 or AAV9 encoding
a modified, N-terminal domain deleted spike protein induces robust cellular immunity and provides longterm protection in k18-hACE2 transgenic mice from lethal SARS-CoV-2 challenge, associated weight loss
and pneumonia independent of vaccine-induced neutralizing humoral immunity. In both mice and
macaques, vaccine-induced cellular immunity results in the clearance of transduced muscle fibers
coincident with macrophage and CD8+ cytotoxic T cell infiltration at the site of immunization. Additionally,
mice demonstrate a strong Type-1 polarized cellular immunophenotype and equivalent ex vivo T cell
reactivity to peptides of wt and alpha (B.1.1.7) variant spike. These studies demonstrate not only that
AAV6 and AAV9 can function as effective vaccine platforms, but also that vaccines can provide long-term
efficacy primarily through the induction of cellular immunity.
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ABSTRACT
A TALE OF TWO TRANSGENES: AAV-DYSTROPHIN AND AAV-SPIKE
REVEAL COMMON THEMES FOR GENE THERAPY AND VACCINES
Christopher Greer
Hansell H. Stedman
Adeno-associated viruses (AAVs) are non-pathogenic, replication
defective viruses that can facilitate long-term gene transfer to a variety of tissues
in vivo. However, the limited DNA packaging capacity of AAV (~5 kb) poses
challenges for the transfer of large genes. Additionally, while AAV is a minimally
immunogenic viral vector, the risk of potential immune response against
exogenous, AAV-delivered transgene products isn’t fully understood. Here I
describe two in vivo AAV-mediated gene transfer projects that utilize engineered,
miniaturized versions of larger genes to overcome the AAV packaging capacity
for the disparate purposes of gene therapy for Duchenne muscular dystrophy
and vaccination against SARS-CoV-2. Duchenne muscular dystrophy (DMD) is a
degenerative X-linked muscle disease caused by mutations that result in the
absence of the giant, rod-shaped structural protein dystrophin. While we have
previously demonstrated that systemic delivery of an AAV-deliverable
miniaturized form of the dystrophin paralog utrophin (AAV-µUtrophin) can
complement for absence of dystrophin without the immunogenicity observed
against similarly designed AAV-µDystrophin, we believe further improvements
can be made to the design of the miniaturized utrophin proteins to improve their
v

functionality and durability. Here we reconstructed the evolution of striated
muscle as well as the piecemeal evolution of the dystrophin gene. Based on this
evolutionary reconstruction of dystrophin’s origin, we propose a structural model
for how the spectrin repeats within the rod domain of dystrophin and utrophin
interact to form a continuous, interlocking structure. Using this structural model of
the dystrophin/utrophin rod domain, we engineered a new AAV-deliverable
utrophin protein (nano4-Utrophin) with a chimeric spectrin repeat capable of
maintaining tensile strength along the entire truncated rod domain. We then
demonstrate that following systemic administration using AAV9, nano4-Utrophin
localizes to the sarcolemma, restores sarcolemmal localization of g-Sarcoglycan,
and prevents ongoing muscle regeneration in mdx mouse model of DMD. While
this project utilized a paralogous protein approach to avoid transgene product
immunogenicity, my second project capitalizes on AAV-delivered exogenous
transgene immunogenicity. I demonstrate that a single intramuscular injection of
AAV6 or AAV9 encoding a modified, N-terminal domain deleted spike protein
induces robust cellular immunity and provides long-term protection in k18-hACE2
transgenic mice from lethal SARS-CoV-2 challenge, associated weight loss and
pneumonia independent of vaccine-induced neutralizing humoral immunity. In
both mice and macaques, vaccine-induced cellular immunity results in the
clearance of transduced muscle fibers coincident with macrophage and CD8+
cytotoxic T cell infiltration at the site of immunization. Additionally, mice
demonstrate a strong Type-1 polarized cellular immunophenotype and equivalent
vi

ex vivo T cell reactivity to peptides of wt and alpha (B.1.1.7) variant spike. These
studies demonstrate not only that AAV6 and AAV9 can function as effective
vaccine platforms, but also that vaccines can provide long-term efficacy primarily
through the induction of cellular immunity.
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CHAPTER 1: Introduction
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1.1 Adeno-Associated Virus (AAV)
1.1.1 Discovery of AAV and Generation of Recombinant AAV
Adeno-associated viruses (AAVs) are non-pathogenic parvoviruses of
the Dependovirus genus that are capable of infecting cells but are replicationdefective without co-infection with a helper virus. While herpesvirus and
baculovirus are efficient helper viruses for AAV, adenovirus is believed to be the
predominant helper virus of AAV in nature. Accordingly, AAV was originally
identified as small, DNA-containing particles that persistently appeared following
inoculation of cells in vitro with AAV-contaminated adenovirus in the 1960s
(Atchison et al., 1965). Intriguingly, when these ~25 nm diameter polygon shaped
particles were purified, they were incapable of replicating in vitro unless cells
were co-inoculated with human adenovirus (Hoggan et al., 1966). In the absence
of helper virus infection, AAV infected human cells in vitro can establish latent
infection by integrating their genome in a predominantly site specific manner into
chromosome 19 (Hastie and Samulski, 2015). In the decades following the
discovery of AAVs, the critical adenoviral helper genes were identified as E1a,
E1b, E2a, E4 and VA RNA. Transfection of cells with a large plasmid expressing
these five adenoviral genes is sufficient to support AAV replication in the
absence of adenovirus infection, making production of AAV feasible without risk
of adenoviral contamination (Xiao et al., 1998).
AAV has a ~4.8 kb single-stranded DNA genome protected within an
icosahedral capsid shell. The single-stranded genome consists of two canonical
genes rep, encoding 4 proteins critical for viral DNA replication (Rep40, Rep52,
Rep68, and Rep78), and cap, encoding 3 structural proteins (VP1, VP2, and
2

VP3) that form the AAV capsid. Additionally, the cap gene encodes a nested, +1frameshifted open reading frame that encodes a protein called AssemblyActivating Protein (AAP) required for capsid assembly in multiple AAV serotypes,
but not in select serotypes such as AAV4, AAV5, and AAV11 (Earley et al., 2017;
Sonntag et al., 2010). The AAV genome is flanked on each side by 145 bp
inverted terminal repeats (ITRs), the only cis-acting genetic elements required for
viral genome replication and packaging of the AAV genome into the capsid
(Samulski et al., 1989). Because the ITRs are the only genetic elements required
for DNA replication and AAV genome packaging, methods have been developed
to generate recombinant AAV (rAAV), where the entire wt AAV genome is
replaced with any gene of interest between the two flanking ITRs. The most
common method to produce AAV is called triple-transfection, which was used to
generate all the rAAV vectors used in this body of work. In triple transfection,
HEK293 cells, which stably express the adenoviral helper genes E1a and E1b,
are transfected with the following three plasmids:
1. Plasmid encoding synthetic genome (transgene of interest flanked
on each side by ITRs).
2. Plasmid encoding adenoviral helper genes E2a, E4, and VA RNA.
3. Plasmid encoding rep and cap of the desired rAAV serotype.
The resulting rAAV now packaging (or harboring) the gene of interest is then
purified from empty vector by a cesium chloride gradient.
3

1.1.2 Potential of rAAV as a Gene Therapy Vector
Gene therapy is the introduction of exogenous DNA to treat genetic
disease (Papanikolaou and Bosio, 2021). Prior to rAAV, gene therapy methods of
delivering exogenous transgenes to tissues in vivo and stably expressing them
were inefficient due to a myriad of issues including, but not limited to, inefficient
DNA delivery, limited duration of transgene expression, and immune targeting of
the transduced cells (Hastie and Samulski, 2015). For example, when
recombinant adenovirus had been used as a viral vector to deliver exogenous
coagulation factor IX (FIX), a protein that when deficient causes hemophilia B, to
muscle, mice only briefly expressed FIX before cellular and humoral immunity
targeted and eliminated the transduced muscle fibers (Dai et al., 1995).
Once methods of generating rAAV were established, multiple groups
began exploring its potential as a gene therapy vector and it was quickly shown
to be capable of delivering exogenous DNA to a variety of tissues in vivo
(Samulski and Muzyczka, 2014). Then In 1996, it was demonstrated for the first
time that rAAV could maintain long-term transgene expression in murine muscle
for >1.5 years following intramuscular administration (Xiao et al., 1996).
Importantly, unlike in vivo recombinant adenovirus administration, there
appeared to be no immune targeting of transduced muscle fibers despite the
expression of a foreign LacZ reporter protein, indicating that AAV was a
4

significantly less immunogenic viral vector than recombinant adenovirus. Another
significant discovery from this early rAAV work was that, unlike wt AAV in vitro,
rAAV-delivered synthetic genomes in vivo did not establish latent infection by
integrating into the transduced cell’s chromosome. Instead, long-term expression
in mice resulted from the rAAV genomes persisting within the nucleus as
concatemerized, circularized episomes (Schnepp et al., 2003; Xiao et al., 1996).
Similarly, it was shown more recently that following intramuscular injection of
rAAV in non-human primates, rAAV genomes are similarly episomal but they are
additionally associated with nucleosomes in a chromatin-like structure (PenaudBudloo et al., 2008). Importantly, these studies showed that in both mice and
primates rAAV provides sustained transgene expression in vivo and this
expression is maintained without genomic integration of the rAAV genome.
Another strength of rAAV for gene therapy is capsid heterogeneity. While
the majority of the early rAAV studies were performed using AAV2, many distinct
AAV serotypes were subsequently discovered that have distinct cell/tissue
tropisms, or distinct relative abilities to transduce different cell types and tissues.
Because rAAV can be generated with a cap gene from any AAV serotype,
irrespective of transgene, each capsid serotype can be utilized to optimally
transduce its target tissue of interest.

5

1.1.3 Challenges of the rAAV Vector Platform
While there are many advantages to rAAV, there are two primary
challenges associated with use of rAAV as a gene therapy vector that relate to
my project: AAV’s limited DNA packaging capacity and the episomal nature of
the AAV genome once transduced.
The first challenge of the rAAV vector platform is that the wt AAV genome
is ~4.8 Kb, which imposes an inherent limit on the amount of DNA that rAAV can
package/transport (Hastie and Samulski, 2015). As the AAV genome increases
in size past >5 Kb, it becomes less efficient at both producing AAV virions as well
as transducing cells with the AAV virions it does generate as it has more recently
been shown that the size of packaged AAV genomes never exceed 5.2kb
(Grieger and Samulski, 2005; Hermonat et al., 1997; Wu et al., 2010). This
inherent “packaging capacity” of AAV makes the exogenous transfer of large
transgenes challenging, especially as the ~5 Kb rAAV genome also must contain
the obligatory ITRs as well as a promoter and PolyA sequence required for
transgene expression.
The second challenge associated with the rAAV vector platform is that
cells transduced in vivo maintain the rAAV genome as an extrachromosomal
episome. While this is advantageous in minimizing the likelihood of insertional
mutagenesis, episomal DNA is not maintained during mitosis. Therefore, if the
cells transduced in vivo undergoes rounds of cell division to facilitate tissue
6

regeneration, the transgene will be lost. This is of particular importance in muscle
and will be discussed in greater depth in the next sub-chapter.

Note: From this point forward, rAAV will be referred to simply as AAV whereas wt
AAV will be referred to as wt AAV.

1.2 AAV Gene Therapy for Duchenne Muscular Dystrophy (DMD)

1.2.1 Striated Muscle Overview
Striated muscle, which includes both skeletal and cardiac muscle, is a
contractile tissue characterized by elongated cells called muscle fibers. Viewed
under interference microscopy, each striated muscle fiber has regularly spaced
stripes, or striations, running its entire length (Huxley and Niedergerke, 1954).
These visible striations are due to the presence of sarcomeres, the functional,
contractile units of striated muscle composed of arrays of “thick” myosin filaments
and “thin” of F-actin filaments complexed with their respective accessory
proteins.
The lateral boundaries of sarcomeres are demarcated by protein dense Zdiscs, that appear as dark electron dense bands on electron micrographs (Fig.
1.1). Z-discs serve as the anchor point for F-actin thin filaments which extend
from the Z-disc towards the center of the sarcomere, another electron dense
7

band called the M-line (Fig. 1.1).
The M-line serves as the anchor
for centering bipolar myosin thick
filaments which extend
bidirectionally from the center of
the sarcomere towards the thin
filaments extending from each
bordering Z-disc (Fig. 1.1).
Finally, the protein titin is required
to scaffold all of these
components into place. Titin is
largest protein in the human
proteome and the third most
abundant protein in striated
muscle after myosin and actin
(Tskhovrebova and Trinick,
2003). Titin spans the halfsarcomere with its N-terminus

Fig 1.1 Sarcomere overview. Electron
micrograph of adult murine skeletal
muscle with the different regions labeled.
Below is a cartoon, aligned with the
micrograph above, of the relevant proteins
present in the various sarcomeric regions.
Note: titin spans entire half sarcomere
although not depicted. [Electron
micrograph of murine skeletal muscle
provided by Dr. Clara Franzini-Armstrong]

localized to the Z-disc and its C-terminus localized to the M-line (Furst et al.,
1988) (Fig. 1.1). Titin is required for sarcomere formation (Chopra et al., 2018),
physically connects the Z-disc to the thick filament, and regulates the length of

B

the thick filament within the sarcomere (Tonino et al., 2017).
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During muscle contraction, all sarcomeres are activated simultaneously in
parallel and in series down the length of the muscle fiber. Within each contracting
sarcomere, the myosin thick filament remains centered at the M-line and pulls the
thin filaments of each overlapping half sarcomere (as well as the attached Z-disc)
inwards towards the M-line, thereby decreasing the total sarcomere distance. As
this occurs, the length of the I-band (region of thin filament not overlapped by
thick filament) decreases; however, there is no change in the length of the Aband (thick filament) (Fig. 1.1). These observations made by interference
microscopy led to the “sliding filament model” of muscle contraction, proposed by
two groups in 1954 (Huxley and Niedergerke, 1954; Huxley and Hanson, 1954).
This model of muscle contraction remains virtually unchanged today.

1.2.2 Dystrophin and Duchenne muscular dystrophy
Within a striated muscle fiber, sarcomeres are organized into tube-like
structures called myofibrils that branch into each other to form a continuous,
mesh-like network collectively called the myofibrillar matrix (Willingham et al.,
2020). The most peripheral portions of myofibrillar matrix directly abutting the
sarcolemma, the specialized plasma membrane of terminally differentiated
striated muscle fibers, establish contacts between Z-discs and the sarcolemma
through focal adhesion-like structures called costameres (Pardo et al., 1983;
Peter et al., 2011). When skeletal muscle contracts, a significant percentage of
9

the contractile force is transmitted laterally from all aligned Z-discs within the
myofibrillar matrix across the sarcolemma and into the surrounding ECM (which
in skeletal muscle is continuous with the tendon) through the costamere, a
process called lateral force transduction (Bloch and Gonzalez-Serratos, 2003;
Peter et al., 2011; Ramaswamy et al., 2011; Street, 1983). Costameres contain
two protein complexes that anchor the sarcolemma to the cortical F-actin
cytoskeleton, the a7/b1-Integrin/talin/viniculin complex and the dystrophin
associated protein complex (DAPC) (Mukund and Subramaniam, 2020). While
homozygous null mutations in the predominantly muscle specific a7-Integrin
ITGA7 gene results in a muscular dystrophy-like phenotype in mice and a rare
non-lethal form of congenital myopathy in humans (Hayashi et al., 1998; Mayer
et al., 1997), mutations that result in loss of dystrophin protein expression lead to
Duchenne muscular dystrophy, the focus of this dissertation.
Duchenne muscular dystrophy is caused by mutations in the dystrophin
encoding DMD gene that result in loss of dystrophin protein expression (Ahn and
Kunkel, 1993). Duchenne muscular dystrophy (DMD) is an X-linked degenerative
striated muscle disease that affects approximately 1 in 5,000 male births (AlZaidy et al., 2017; Mendell et al., 2017). Duchenne muscular dystrophy is

10

characterized clinically

A

by progressive muscle
degeneration and
weakness, loss of
ambulation in most

B

cases by age 12,
required mechanical
ventilation in the early
twenties, and death in
the late thirties resulting
from cardiovascular

Fig. 1.2 Dystrophin nucleates dystrophinassociated protein complex formation at
costameres. (A) The muscle specific isoform of
dystrophin, Dp427m, is a rod-shaped protein
consisting of an N-terminal actin-binding domain
(ABD) (itself composed of 2 tandem CH domains), a
rod-domain of 24 triple helical spectrin repeats, a βdystroglycan binding cysteine-rich region (CRR),
and a C-terminal region (CTR). (B) Schematic of the
dystrophin-associated protein complex present at
costameres.

and respiratory failure
(Emery, 2002; Ryder et
al., 2017). The muscle
specific isoform of
dystrophin (Dp427m) is
a 427 kilodalton, rod-

shaped cytoskeletal protein expressed in fully differentiated striated muscle fibers
(Ahn and Kunkel, 1993; Doorenweerd et al., 2017). Dystrophin consists of four
major regions: 1. An N-terminal actin-binding domain (ABD) that binds to the
cortical F-actin cytoskeleton, 2. A large central rod region consisting of 24

B

individual triple alpha helical spectrin repeat domains (SRs) (Fig. 1.2A) that align
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end-to-end to form a ~150 nm long rod structure, 3. A cysteine-rich region (CRR)
that anchors dystrophin to the transmembrane protein β-dystroglycan, and 4. A
C-terminal region (CTR) (Fig. 1.2A) (Duan et al., 2021). Dystrophin is expressed
in developmentally mature striated muscle fibers and it is recruited to the
sarcolemma through its interaction with the cytoplasmic tail of the
transmembrane protein β-dystroglycan (Huang et al., 2000; Jung et al., 1995;
Zubrzycka-Gaarn et al., 1988). β-dystroglycan forms a linkage to the EMC
through its tight extracellular association with the glycoprotein a-dystroglycan
which binds the EMC protein laminin in the muscle fiber basil lamina (Fig. 1.2B)
(Gao and McNally, 2015; Ibraghimov-Beskrovnaya et al., 1992). Therefore,
through simultaneously binding the sub-sarcolemmal g-actin cytoskeleton and βdystroglycan, dystrophin mechanically links the cytoskeleton and the surrounding
extracellular matrix through the sarcolemmal membrane at costameres (Fig.
1.2B) (Hanft et al., 2006). Additionally, costameric dystrophin recruits and
localizes other dystrophin-associated protein complex members, including the
transmembrane sarcoglycan family of proteins, to the sarcolemmal membrane
which further stabilizes the mechanical linkage to the ECM (Fig. 1.2B) (Davies
and Nowak, 2006).
In the absence of dystrophin protein, as is the case in both Duchenne
muscular dystrophy as well as in the dystrophin-deficient mdx mouse model of
DMD, loss of dystrophin additionally results in the absence of all other
dystrophin-associated protein complex members from the sarcolemmal
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membrane (Davies and Nowak, 2006). When dystrophin and the dystrophinassociated protein complex are absent from the membrane, the sarcolemma is
rendered susceptible to damage from contraction-induced mechanical forces,
inevitably leading to the DMD phenotype (Petrof et al., 1993).

1.2.3. AAV Gene Therapy for DMD
Small molecule therapeutics are incapable of compensating for loss of
dystrophin due to its complex scaffolding and biomechanical properties within
muscle; consequently, AAV-mediated gene therapy to replace the missing
dystrophin has been an area of intense interest as a potential treatment or cure
for DMD. AAV is an ideal vector for DMD because unlike adenoviral vectors it is
minimally immunogenic and multiple serotypes, such as AAV6 and AAV9, are
capable of systemically transducing skeletal and cardiac muscle following
intravenous injection (Gregorevic et al., 2004; Wang et al., 2005).
Because the ~14 Kb cDNA of dystrophin far exceeds the ~5Kb packaging
capacity of AAV, a major challenge in the development of AAV gene therapy for
DMD has been the development of AAV-deliverable, miniaturized dystrophin
(μDystrophin) transgenes that retain the functionality of full-length dystrophin.
μDystrophin transgenes consisting of the critical N-terminal actin-binding domain
and the β-dystroglycan binding CRR connected via a significantly truncated rod
domain (Fig. 1.3B) have been shown to provide significant therapeutic benefit in
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mdx mice when expressed either transgenically or following systemic AAV
transduction (Harper et al., 2002; Phelps et al., 1995). However, an initial Phase I
DMD clinical trial revealed that patients that had received a single intramuscular
injection of AAV-μDystrophin subsequently mounted a systemic T cell response
against the μDystrophin transgene product (Mendell et al., 2010).
To preclude any possibility of immunogenicity against the therapeutic
transgene, the Stedman lab has focused on developing an analogous AAVμUtrophin based gene therapy for DMD. Utrophin is a paralog of dystrophin that
arose from a gene duplication of the ancestral dystrophin/utrophin (dys/utr) gene
in the common ancestor to all jawed vertebrates (Fig. 1.3A). Having arisen from
a gene duplication of the ancestral dys/utr gene, the only difference between the
multi-domain architecture of dystrophin and utrophin is that utrophin’s rod-domain
has 22 spectrin repeats rather than 24 as in dystrophin and the singular dys/utr
protein in lineages that diverged prior to the gene duplication, such as sea urchin
(Fig. 1.3A, B). Like dystrophin, utrophin nucleates costameric DAPC formation
and mechanically couples the cortical cytoskeleton and EMC through its
interaction with β-dystroglycan (Hnia et al., 2007). The primary difference
between dystrophin and utrophin is their developmental and spatial expression
pattern, with expression of utrophin limited to regenerating muscle fibers and
then being restricted to the myotendinous and neuromuscular junctions of
terminally differentiated, non-regenerating muscle fibers (Deconinck et al., 1997).
Importantly, evidence that utrophin can compensate for dystrophin comes from
14

the fact that transgenic over-expression of utrophin in the mdx mouse improves
the dystrophic phenotype (Tinsley et al., 1998). Additionally, utrophin is
endogenously upregulated in mdx mice and mdx/Utrophin-/- double knock out
mice display an exacerbated dystrophic phenotype (Deconinck et al., 1997). Like
mdx mice, utrophin is endogenously upregulated in DMD patients and disease
severity correlates with utrophin expression (Kleopa et al., 2006).

Fig. 1.3 Evolution of utrophin and therapeutic µDystrophin and µUtrophin
transgenes. (A). Reconstructed timeline of the ancestral dystrophin/utrophin
gene duplication (@). Lineage-specific utrophin spectrin repeat deletions in the
lineage leading to humans (%, #). MYA, million years ago. (B) Aligned protein
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domain architecture for dystrophin/utrophin protein family members in various
lineages from (A) as well as the µDystrophin and µUtrophin transgenes derived
from the full-length sequences. Spectrin repeat deletions from (A) (%, #) are
mapped onto the human utrophin primary structure relative to the shark
sequence, where utrophin maintains the ancestral dys/utr 24 repeat length.
(Figure adapted from (Song et al., 2019)).
While all of this suggests that utrophin is capable of compensating for
dystrophin deficiency, we hypothesized that because utrophin is expressed in
DMD patients, AAV-delivered μUtrophin transgenes will additionally be protected
by central immunological tolerance, the process by which auto-/self-reactive T
and B cells are eliminated to prevent autoimmunity.
To formally the hypothesis that Dystrophin based transgenes could drive
immunotoxicity in a large animal deletional-null model of Duchenne muscular
dystrophy, our lab utilized the German shorthaired pointers (GSHPMD) canine
model (Schatzberg et al., 1999; VanBelzen et al., 2017). This canine model has a
deletion spanning the entire dystrophin encoding DMD gene and therefore lacks
central immunological tolerance against any dystrophin epitope. We injected
dogs intramuscularly with 2E12 vg/kg AAV-μDystrophin and AAV-μUtrophin (Fig.
1.3B) in opposite tibialis anterior muscles and using an Interferon-g ELISpot
assay on peripheral blood mononuclear cells observed the presence of a
systemic T cell-mediated immune response against μDystrophin as early as 2
weeks post AAV injection (Song et al., 2019). This systemic cellular immune
response against dystrophin was sustained for two months post AAV injection,
the length of the experiment, and was never observed against μUtrophin. This
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systemic immune response against μDystrophin was also associated with
inflammation and loss of μDystrophin transgene expression in the AAV9μDystrophin treated muscle. There was no comparable inflammation or loss of
μUtrophin in the AAV9-μUtrophin treated muscle (Song et al., 2019). This
confirmed both that a cellular immune response could be mounted against AAV
delivered exogenous, “non-self” transgenes expressed in muscle (at least in this
animal model with this vector dose and route of administration) and that
μUtrophin avoided this fate due to central tolerance afforded to this native
paralogous protein.
Additionally, AAV9-μUtrophin also completely protected against the
dystrophic phenotype in mdx mice at 2 months of age following neonatal
systemic injection of 1E14 vg/kg (Song et al., 2019).

1.3.4 Remaining Challenges Facing Gene Therapy for DMD
One of my first experiments upon joining the Stedman lab involved
performing western blots on muscles from AAV9-μUtrophin treated mdx mice to
demonstrate homogenous muscle biodistribution of μUtrophin transgene
expression. When I stained muscle with an N-terminal utrophin antibody I
occasionally observed a ~75 kDa band underneath the ~140 kDa μUtrophin band
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(Fig. 1.4B). This molecular
weight corresponded with
the estimated weight of the
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repeat 3 and spectrin
repeat 22 (Fig. 1.4A, B). To
test if this was the Nterminal portion of
μUtrophin somehow
breaking or being
proteolyzed at the internal
deletion site, the ~75 kDa
area of the polyacrylamide
gel was cut out and liquid
chromatography–tandem

Fig. 1.4 Fragmentation of µUtrophin. (A)
Schematic of µUtrophin generation and
domain architecture. (B) Western blot of mdx
gastrocnemius (GM) muscles following
neonatal IP injection with either PBS
(untreated) or AAV9-µUtrophin. Schematic
shows what portion of µUtrophin the band
represents and where the N-terminal
antibody is binding to µUtrophin.

mass spectrometry (LC-MS/MS) was performed to identify peptides present in
the band. When all the identified peptides were aligned to our μUtrophin
transgene sequence, they aligned up until the internal deletion site but not past it,

18

thereby confirming that the ~75 kDa band we were observing by western blot
was an N-terminal fragment of µUtrophin (Fig. 1.4B).
This poses a potential risk for the durability of μUtrophin and μDystrophin
based therapies alike, as similar fragments have been observed in μDystrophin
studies but have gone unexplored (Harper et al., 2002). Molecular breakage of
μUtrophin and μDystrophin proteins at this site would create a C-terminal
fragment consisting of just one spectrin repeat and the CRR domain. Previous
studies have shown that expression of a similar dystrophin CRR domain in
wildtype skeletal muscle induces a dystrophic phenotype by competing with fulllength dystrophin for limited b-dystroglycan binding sites (Leibovitz et al., 2002).
If, through this mechanism or any other, μUtrophin/μDystrophin fragmentation
were to allow skeletal muscle damage, muscle regeneration would lead to
progressive loss of transduced myonuclei. This is because skeletal muscle
regeneration is mediated by muscle stem cells that, in response to muscle
damage, generate a population of transiently amplifying progenitors called
myoblasts that then fuse with the damaged muscle fibers to replace the damaged
nuclei (Relaix et al., 2021; Tedesco et al., 2010). As myoblasts divide, they will
lose any episomal AAV genomes and then as they fuse with the transduced
muscle fibers, they will replace AAV transduced myonuclei with new
untransduced nuclei. Overall, this creates a motivation to engineer second
generation μUtrophin/μDystrophin transgenes that do not fragment and risk the
durability of the therapy.
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1.4 Coronaviruses and SARS-CoV-2
Coronaviruses are large, enveloped RNA viruses that infect both animals
and humans and cause a variety of diseases, such as lethal peritonitis in felines
(Hartmann, 2005), demyelinating neurological disease in rodents, and respiratory
disease in chickens and humans (Perlman and Dandekar, 2005). Prior to 2002,
four coronaviruses were known to be endemic to the human population (HCoV
229E, NL63, OC43, and HKU1), cumulatively accounting for up to 20% of common
cold cases worldwide (Gaunt et al., 2010; Graat et al., 2003; van Elden et al.,
2004). While most respiratory illnesses resulting from endemic human coronavirus
infections are mild, severe disease can occur, particularly in infants and
immunosuppressed individuals (Corman et al., 2018; Konca et al., 2017).
However, in 2002 and 2012 two novel zoonotic coronaviruses named severe acute
respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory
syndrome coronavirus (MERS-CoV), respectively, emerged in the human
population and caused lethal outbreaks of respiratory disease (de Wit et al., 2016;
Drosten et al., 2003; Rota et al., 2003; Zaki et al., 2012). While both SARS-CoV
and MERS-CoV were highly lethal, human-to-human transmission was
predominantly nosocomial, occurring within a hospital setting, thereby likely
limiting the scale of the resulting outbreaks (de Wit et al., 2016).
In 2019, a third novel coronavirus was found in patients with severe
pneumonia in Wuhan, China (Huang et al., 2020a; Worobey, 2021). This novel
coronavirus was found to be similar in sequence to the 2002 SARS-CoV virus and
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96% identical to a previously identified bat coronavirus, indicating a likely bat origin
of the new coronavirus (Zhou et al., 2020). Due to the genetic similarity between
the novel coronavirus and SARS-CoV, the new virus was named severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) and the disease attributed to
SARS-CoV-2 infection was named Corona Virus Disease-2019 (COVID-19).
Airborne human-to-human transmissibility of SARS-CoV-2 and viral shedding prior
to the onset of symptoms, neither of which were prominent with SARS-CoV or
MERS-CoV, have contributed to SARS-CoV-2 causing a multi-year global
pandemic.
Like all coronaviruses, SARS-CoV-2 infects cells using a homotrimeric
transmembrane glycoprotein called spike that projects from its enveloped virion
and binds membrane-bound receptors on target cells to mediate the fusion of the
viral and cellular membranes (Huang et al., 2020b; Tortorici et al., 2019). The
receptor for SARS-CoV-2 in humans is angiotensin-converting enzyme 2 (ACE2)
(Zhou et al., 2020). ACE2 is expressed on airway epithelial cells, thereby
facilitating respiratory tract infection. Additionally, ACE2 is expressed in
cardiomyocytes, endothelial cells, and pericytes, and recently it was recently
reported that SARS-CoV-2 infection leads to viral myocarditis in macaques,
potentially explaining cardiac complications that have been observed in COVID-19
(Feng et al., 2021).
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1.4 Goals of Project
This project consists of two disparate sub-projects, connected by the
common theme of overcoming the inherent DNA packaging capacity of the AAV
vector platform to yield clinically beneficial outcomes.
Chapter 2 explores the evolution of striated muscle and the emergence of
the critical muscle proteins titin and dystrophin. Based on the evolutionary
reconstruction of dystrophin’s origin, I developed a structural model for how
spectrin repeats within the rod domain of dystrophin, and therefore its paralogous
protein utrophin, overlap and interact to form a continuous, interlocking structure.
Using this model, I explore whether I can generate a second generation AAVdeliverable utrophin-based transgene for the treatment of DMD and test whether
it is capable of correcting for the absence of dystrophin in the mdx mouse model.
Chapter 3 builds off our lab’s observation that AAV-delivered µDystrophin
is immunogenic following intramuscular injection in the GSHPMD canine model
of DMD. In response to the COVID pandemic I explored whether miniaturized,
AAV encoded spike proteins were capable of inducing an immune response
against spike following intramuscular injection. I also wanted to characterize the
nature of the immune response and determine whether the AAV-spike induced
immune response was sufficient to function an effective SARS-CoV-2 vaccine
and protect humanized hACE2 transgenic mice against lethal SARS-CoV-2
infection.
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CHAPTER 2: Evolutionary reconstruction of muscle and scalable
locomotion suggests improved AAV-deliverable utrophin
transgene for Duchenne muscular dystrophy gene therapy

The contents of this chapter have been submitted for publication as:
Christopher D. Greer, Yafeng Song, Derek Stefanik, Leon Morales, Benjamin
Kozyak, Alock Malik, Shira T. Rosenblum, Mohammed Haider, Ranjith
Krishnankutty, Hansell H. Stedman. Evolutionary reconstruction of muscle
and scalable locomotion suggests improved AAV-deliverable utrophin
transgene for Duchenne muscular dystrophy gene therapy
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2.1 Abstract
The molecular basis of the early evolutionary transition from small animal species
with dynein-powered locomotion to massive species powered by myosin is poorly
understood. Previous studies suggested that sarcomeres arose independently in
Cnidaria in the absence of scaffolding proteins homologous to the vertebrate
titins. We find high molecular weight titin orthologs in representative species of
three Cnidarian classes, implying their existence in a cenancestor and a single
evolutionary origin of striated muscle. In the absence of mesoderm-derived
tissues, allometric scaling of muscle in cnidarians occurs via fractal folding of
their epitheliomuscular sheet. We show that an ancestral dystrophin ortholog
consisting of just the C-terminal cysteine-rich region and C-terminal domain and
the entire membrane spanning dystrophin-associated protein complex emerged
far before skeletal muscle in unicellular eukaryotes. Gene structures provide
evidence that full-length dystrophin arose from a partial gene duplication of an
ancestral MACF1 ortholog encoding an N-terminal actin binding domain and 24
spectrin repeats became linked in cis to the gene encoding the ancestral Cterminal dystrophin ortholog. These findings frame the chronology of innovations
associated with the emergence of scalable locomotive power and provide novel
insight into the mechanobiology of dystrophin and its paralog utrophin. Building
off these evolutionary insights, we designed a miniaturized, Adeno-associated
virus (AAV) deliverable utrophin protein for the treatment for Duchenne muscular
dystrophy (DMD) and demonstrate its effectiveness at complementing for
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dystrophin in the mdx mouse model of DMD. We believe these insights will lead
to the development of more durable AAV gene therapies for DMD.

2.2 Results
The traceable ancestry of the motor proteins dynein and myosin predates
the eukaryotic cenancestor, while that of their sliding filament partners tubulin
and actin, respectively, predates the divergence of archaea and eubacteria (Fu et
al., 2018; Lowe and Amos, 1998; Nogales et al., 1998; van den Ent et al., 2001).
Both systems harness ATP to generate power strokes of similar magnitude;
however, they differ fundamentally in the scalability of their respective locomotive
organelles, cilia and sarcomeres (Fig. 2.1). The limited size and speed of species
of the earliest-branching metazoan phyla Ctenophera (Colin et al., 2010; Moroz
et al., 2014; Ryan et al., 2013) and Placozoa (Srivastava et al., 2008) illustrates
the inherent limitation of the dynein-powered ciliary locomotive apparatus, with
scaling of cilia proportional to the surface area rather than the mass of the
organism (Fig. 2.1A). In contrast, the concatenated bipolar filament structure of
sarcomeres enables their networked assembly, in parallel and in series, within
the interior of densely adherent cells to power arbitrarily large and forceful
macroscopic movement in larger species (Fig. 2.1C). The impact of sarcomeres
is apparent in the next branching phylum, Cnidaria (Putnam et al., 2007), where
the largest extant species exceed 2 m in diameter and swim at 1 meter/second
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(Fig. 2.1D) (Kawahara et al., 2006; Lee et al., 2010). Cambrian fossils reveal
scaling to a diameter of > 70 cm by 510 MYA (Hagadorn et al., 2002), suggesting
that then, as now, increasing size and speed are positively correlated with
Darwinian fitness, survival, and trophic level among individuals within complex
food webs (Dicken et al., 2017; Le Galliard et al., 2004; Romanuk et al., 2011).
Important, unresolved mysteries include the molecular basis of sarcomere
assembly and the cellular basis of locomotive power scaling in these diploblasts,
despite the absence of a mesoderm-derived circulatory apparatus to support the
aggregate metabolic demands of myosin ATPase.

A

B

C

D

Fig. 2.1 Overview of differentially scalable locomotive organelles, their
respective motor proteins, and the animals that employ them. (A-B)
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Schematic of locomotive motor protein dynein within cilia. Cilia are arrayed in a
rim protruding from the organism’s surface, thus scaling at no greater than the
2/3rd’s power of body mass. (C) Schematic of locomotive motor protein myosin
within sarcomeric muscle. Sarcomeric locomotion is powered by sarcomeres,
intracellular organelles that use bipolar filaments of the motor protein myosin
(present within the A-band of the sarcomere) to walk along actin filaments to
generate mechanical force. (D) Branch order, phylum, locomotive motor
protein(s), length, mass, and speed (both absolute and as ratio to length: L/S) for
selected eukaryotic species. Dynein’s ATPase is responsible for
mechanochemical energy transduction and the comparatively rapid motility of
unicellular eukaryotes, while myosin’s ATPase is dominant locomotive motor
protein in all metazoan phyla branching after the emergence of sarcomeres.
In Cnidarian ephyra, or larvae, sarcomeres are distributed uniformly
around the circumference of the ephyra (Fig. 2.2, A-D). However, as they grow
to adult medusa, sarcomeric muscle is localized to the basal compartment of
polarized epithelial cells constituting the subumbrellar epidermis (Fig. 2.2, E and
F). As this anatomic constraint precludes true three-dimensional scaling of
muscle as the organism grows, we investigated the muscle morphology in larval
and mature specimens to understand how the largest species produce sufficient
power to rapidly propel a mass of 200 kg. We found that in adult medusa the
sarcomeric pole of the epitheliomuscular cell sheet convolutes in a plane
orthogonal to the direction of the myofibrils, with the creation of self-similar folds
at several levels of magnification (Fig. 2.2E, F, F’, and G’). The fractal
dimension enables these species to adequately scale power throughout growth
(i.e. myosin scales at approximately the 2.5th power of mass) (Mandelbrot, 1967;
West et al., 1999). However, this folding together with the absence of a
circulatory system requires that a novel biophysical limitation be addressed: the
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need for high energy flux to support the sarcomeric myosin ATPase as the
distance separating myofibril from oxygen source (sea water) increases with the
extent of folding (Fig. 2.2F and G’). Staining for mitochondrial complexes IV and
V reveals extreme polarization of the electron transport chain across the cell
(Glancy et al., 2015), co-localizing cytochrome c oxidase with environmental
oxygen in the apical compartment and ATP synthase with the contractile
apparatus in the basal compartment of the polarized epitheliomuscular sheet
(Fig. 2.2G and G’). Additionally, although diploblasts lack true mesoderm, we
interpret the sparse but homogeneous distribution of migratory ECM-secreting
cells in the mesoglea (Fig. 2.2F) as reflecting the requirement for threedimensional scaling of the elastic hydroskeleton that is necessary for sarcomeres
to reciprocate (re-lengthen) during “Scyphozoan diastole.” We propose that the
low metabolic rate of these mesogleal cells allows them to survive despite the
extraordinarily low gradient for gas exchange across large diffusion distances
from the perimeter.
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Fig. 2.2. Anatomy of scalable energy flux in jellyfish. (A-D) Confocal image of
5mm Aurelia aurita ephyra with serial magnification of inset regions. Up to this
developmental stage it is possible to visualize every sarcomere (red-phalloidin) in
the larval jellyfish because of the sheet-like alignment of the epitheliomuscular
cells. (E) Mature blue blubber jellyfish (Catostylus mosaicus) showing swimming
musculature visible with the unaided eye. (F) Immuno-fluorescent micrograph
showing the fractal folding pattern of the sarcomeric sheet (red) with additional
stains revealing the relative positions of the epitheliomuscular cell nuclei (blue)
and mitochondrial cytochrome oxidase (magenta). Note comparatively sparse
distribution of dual-stained cells in mesoglea. (F’) Cartoon depiction of the
orientation of the long axes of the myofibrils orthogonal to the folding pattern in
(F). (G) Extraordinary asymmetry of mitochondrial cytochrome oxidase
(magenta) and ATP synthase (green) in serial section corresponding to inset
region in (F). (G’) As in g, also stained for F-actin with phalloidin (red) to reveal
proximity to site of ATP synthesis.
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To address the evolutionary origins of the Cnidarian myofibers, we
focused our attention on candidate orthologs of titin and dystrophin, giant repeatcontaining scaffolding proteins of vertebrate sarcomeres and costameres,
respectively. Mutations in each of these proteins have been implicated in human
myopathies. Vertebrate titins serve in monomeric form as the primary scaffold for
sarcomere formation (Chopra et al., 2018; Tonino et al., 2017; Tskhovrebova and
Trinick, 2003; Zoghbi et al., 2008), and are primarily composed of
immunoglobulin (IgG) and fibronectin type-III (Fn3) domains flanked by unique Nand C-termini localized to the Z-disc and M-line, respectively (Fig. 2.3, C and D).
Titin homologs have not been found in diploblasts (including cnidaria) (Steinmetz
et al., 2012), and those previously identified in invertebrate triploblasts are widely
divergent in number, primary structure, domain composition, and length,
complicating the delineation of functional orthology (Tskhovrebova and Trinick,
2003). In analyzing publicly available genomes for genes encoding canonical
IgG/Fn3 repeats we noted cis linkage of unambiguous orthologs to the unlinked
human genes titin, obscurin, and myomesin on a single genomic scaffold for the
invertebrate chordate B. floridae, suggesting that an ancestral gene of this overall
structure split into at least three distinct genes early in vertebrate evolution (Fig.
2.3B and C). We then found evidence of cis linkage between the 5’-end of
orthologous titin-obscurin “supergenes” and a highly conserved tandem spectrinlike repeat domain in genomes representing many lineages (Fig. 2.3B and C;
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Fig. 2.4). We searched for transcriptional read-through in mRNA from a broad
sampling of taxa and discovered that this N-terminal extension is co-expressed
with the putative titin orthologs in invertebrates, but not vertebrates, despite
conservation of homologous sequences in both (Fig. 2.3B and C; Fig. 2.4A-C).
This conserved N-terminal titin extension allowed us to identify and
unambiguously establish the orthology of expressed titin genes in Cnidaria (Fig.
2.3B). The overall structural similarity between the titin orthologs of Cnidaria and
Cephalochordates implies common decent from an ancestral titin ortholog that
has undergone extensive genomic rearrangement and modular repeat
expansions in most lineages, including humans (Fig 2.3B and C). The inferred
structure of this ancestral titin ortholog includes 3 regions: 1, N-terminal spectrinlike repeat region orthologous to human CCDC141, 2, a canonical titin-like IgG
(+/- Fn3) repeat region, and 3, a C-terminal region orthologous to human
Obscurin with an SH3-RhoGEF-PH domain triplet and ³1 protein kinase domain
(Fig. 2.3B and C; Fig. 2.4). We therefore propose a model in which the
molecular inception of the ancestral titin ortholog in a common ancestor to
Cnidaria and Bilateria represents the synapomorphy critical to the genesis of
sarcomeres. In contrast to an alternative model for convergent evolution
(Steinmetz et al., 2012), we assert that the earliest, shortest sarcomeres
depended on the scaffolding function of titin, arose first in epithelial cells of
diploblasts, and drove the emergence of epitheliomuscular cells resembling
those of extant Cnidaria. In later-branching triploblasts, expression of titin and
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other lineage-specific sarcomeric proteins in mesoderm-derived myocytes
conferred additional selective advantage by enabling true three-dimensional
locomotive scalability, with mitochondrial gas exchange supported by circulatory
and/or tracheal convection.

Fig. 2.3 Molecular evolution of titin correlates with the emergence of
sarcomeres. (A-C) For each metazoan species (row), the largest titin-like
structural homologs are depicted. In cases where both gene model and
expressed mRNA are indicated, each depiction represents the largest de novo
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predicted ORF encoded within the locus. This is only disambiguated in N.
vectensis, where the spliced out regions accounting for the size disparity
between the gene model and expressed mRNA are underlined in the gene
model. (A) The earliest branching metazoan lineages lack both sarcomeric
muscle and titin-like structural homologs. The genome of T. adherens contains
physically linked genes encoding homologues to the N- and C-terminal regions of
the titin orthologs (Fig. S4). (B) All lineages branching after T. adherens have
sarcomeres and express titin orthologs with >100 tandem Ig and/or Fn3 domains.
The titin ortholog expressed in this group of invertebrates has an N-terminal
spectrin repeat region. (C) Z-repeats are unique to the N-termini of vertebrate
titin orthologs. This evolutionary innovation coincides with the fragmentation of
the ancestral titin N-terminal region into the independently expressed vertebrate
genes SESTD1 and CCDC141 (Fig. S3). (D) Electron micrograph of a single
sarcomere from vertebrate skeletal muscle. Arrows indicate the orientation of
vertebrate titin, and other ancestral titin supergene components, within the hemisarcomere.
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Fig. 2.4 Emergence of Z-repeats coincides with fragmentation of the
conserved N-terminal portion of the ancestral titin supergene into SESTD1
and CCDC141 in vertebrates. (A) Genomic map of human chromosome 2 in the
region encoding titin (***) as well as its two upstream genes SESTD1 (*) and
CCDC141 (**). (B) Expression of ancestral Titin locus gene products in selected
taxa. Expression of the ancestral N-terminal spectrin repeat region is observed at
the mRNA level from cnidarians through echinoderms; however, in vertebrates
this N-terminal region is no longer co-expressed with titin and it is instead
expressed as the two independent genes SESTD1 (*) and CCDC141 (**).
Coinciding with the fragmentation of the ancestral titin N-terminus in vertebrates,
Elephant shark is the earliest branching species with HMM identifiable Z-repeats.
(C) 25% minimum ID dot matrix comparing the first 5,000 a.a.’s of the
echinoderm (P. lividus) titin ortholog (Y-axis) vs the first 5,000 a.a.’s of
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concatenated SESTD1(*), CCDC141(**), and titin (***) from Elephant shark (Xaxis). Two Z-repeats (each on their own Phase 0/0 exon) have been inserted into
the poly IgG region of Elephant shark titin. (D) 25% minimum ID dot matrix
comparing the first 5,000 a.a.’s of concatenated SESTD1(*), CCDC141(**), and
titin (***) from Elephant shark (Y-axis) vs. the first 5,000 a.a.’s of the
corresponding human orthologs (X-axis).
With increasing power density in the cytoplasm attributable to titin’s
scaffolding of sliding actin and myosin filaments, the mechanical energy flux
across the cell membrane must proportionately increase. In a wide range of
bilateria, including vertebrates and ecdysozoa, membrane stabilization and
protection from injury during energy transfer is accomplished by costameres,
essential, cortical protein-dense structures in which the dystrophin associated
protein complex provides mechanical linkage between the outermost sarcomeres
and the extracellular matrix (Hoffman et al., 1987). Approximately 75% of
dystrophin’s molecular weight in humans is contributed by a large central “roddomain” composed of 24 spectrin-like repeat domains, with the flanking domains
establishing adhesive contacts to actin and b-dystroglycan at opposite ends (Fig.
2.6A). While absence of functional dystrophin results in the severe phenotype of
Duchenne muscular dystrophy, both in-frame truncating deletions and
lengthening duplications in the rod domain result in milder disease of variable
severity (Becker muscular dystrophy), begging the question of whether evolution
has optimized the extraordinary length of dystrophin’s rod. This question is
central to therapy for these diseases, as vectors for systemic gene delivery have
packaging limits one-third the size of dystrophin. We therefore asked whether the
number of spectrin-like repeats in dystrophins grew under selective pressure
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after the emergence of sarcomeres, perhaps correlating with increasing power
output in selected taxa during the evolution of hierarchical, predatory food chains.
An ancestral dystrophin in existence before the Cnidarian-Bilatarian split is
predicted to have had a rod domain virtually identical length to that in humans
(Fig. 2.5; Fig. 2.6C). Our phylogenetic analysis provided strong evidence that the
membrane-spanning dystrophin-associated protein complex (DAPC) emerged far
earlier than metazoan multicellularity, with orthologs of nearly all muscle-diseaseimplicated components present in the unicellular sister groups to metazoa (Fig.
2.5). However, the first dystrophin orthologs were lacked both a rod-domain and
an N-terminal actin binding domain (ABD) (Fig. 2.5; Fig. 2.6C). The earliest
branching lineage with a rod-like dystrophin ortholog (i.e. an N-terminal ABD and
an elongated rod-domain) is the Placozoan species T. adherens in which the rod
domain is of similar size to that of humans (Fig. 2.6C). Thus, dystrophin achieved
“full length” from its inception, prior to the emergence of sarcomeres.

Fig. 2.5 Phylogenetic distribution of dystrophin-associated protein complex
proteins and their associated glycosylases and ECM ligands. For each
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protein, or specific modules of a protein, it’s phylogenetic presence in the
indicated species is indicated. Forms of muscular dystrophy that arise from lossof-function mutations in these proteins in humans are indicated. For dystrophin
itself, the number indicates the number of spectrin repeats present in that
species.

Fig. 2.6 The length of the Dystrophin rod was established prior to the
emergence of sarcomeres. (A) Human dystrophin gene, mRNA, and Protein
domain structure aligned to demonstrate intron position and phasing. 22 of 24
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spectrin repeats of human dystrophin contain a phase 0 intron at HMM position
46 (red dots). Cnidarian dystrophin shares rod-domain phase 0 introns (for clarity
only HMM position 46 phase 0 introns are depicted in the cnidarian mRNA). (B)
Human beta heavy spectrin, dystrophin, and MACF1 depicted with the rod
domains vertically aligned to a consensus sequence for the triple helical domain
HMM. Superimposed are the positions and phases of introns relative to the
corresponding coding sequences. For clarity, only introns shared with
orthologous genes from the most distantly related species are shown, with the
spectrin gene showing vestigial introns (arrow) from a remote partial gene
duplication of 13 repeats (spectrin – A. queenslandica; dystrophin - N. vectensis;
MACF1 – T. adhaerens). (C) Phylogenomic distribution of alpha-actinin protein
superfamily members in select eukaryotic lineages. The number of rod-domain
spectrin repeats is specified in parenthesis. Members of the dystroplakin
superfamily harbor phase 0 introns at HMM position 46, whereas alpha-actinin
and spectrin family proteins lack conservation of a phase 0 intron at this position.
HMM 46 intron-driven expansion of the ancestral MACF1 ortholog is observed
between fungi and Placozoa.

We next addressed the question of when and how dystrophin’s rod grew
in length by identifying an ancestral character state that evolved more slowly than
individual amino acids or nucleotides within a sequence: the position and phase
of introns relative to coding sequences for tertiary structural domains scored by
hidden Markov modeling (HMM). We discovered that spectrin-like repeats of
dystrophin and another homolog, microtubule-crosslinking factor1 (MACF1),
share conserved phase 0 introns at the spectrin repeat HMM consensus position
46, sharply contrasting with the randomly distributed introns present within the
spectrin repeats of the spectrin family of proteins (Fig. 2.6A and B). Illustration of
the evolutionary stasis of intron positions is accentuated by depicting only those
shared in orthologous genes of remotely related species (Fig. 2.6B). This
character state analysis identifies an MACF ortholog, not a beta-spectrin, as the
proximate donor of dystrophin’s N-terminal ABD and rod domains, suggesting the
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name “dystroplakin” for this cladistic group (Fig. 2.6C). The gene structures
constitute strong evidence that dystrophin arose from a partial gene duplication
of an ancestral MACF1-like spectroplakin encoding an N-terminal actin binding
domain and 24 spectrin repeats became linked in cis to the gene encoding the
ancestral dystrophin ortholog consisting of only the cysteine-rich region (CRR)
and C-terminal region (CTR) of dystrophin (Fig. 2.6C). This supports a
reconstruction in which the selective pressure for progressive lengthening of the
rod domain occurred (and in some lineages continues) in the cellular context of a
microtubule-actin crosslinking “strut”, but not in that of dystrophin per se.
Homology modeling of the dystrophin rod domain using the MACF1related protein plectin as the homology model template suggests that the spectrin
repeats of the dystrophin rod domain have extensive amino acid interactions
between overlapping adjacent spectrin repeats (Fig. 2.7C, D). This “interlocking
chain” model is distinct from the alternative “beads on a string” model you
observe when you model the dystrophin rod using the evolutionarily unrelated
beta2-spectrin protein as the homology model template. In this instance there are
no amino acid interactions between adjacent spectrin repeats (Fig. 2.7B, D). In
the interlocking chain model, amino acid interactions between adjacent repeats
would have co-evolved (Marks et al., 2012) to maintain tensile strength across
the “interlocking” triple helical spectrin repeats of the dystrophin rod domain to
aid in longitudinal force transmission, the known function of the dystrophin
protein. Under these circumstances, purifying selection would have negatively
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selected against the novel juxtaposition of non-adjacent spectrin repeats by
internal gene deletion or duplication (as observable in Becker muscular
dystrophy pathogenesis). If the rod domain’s tensile STRENGTH is the primary
focus of evolutionary constraint on the rod domains length, then the 24-repeat
length in mammals is simply a byproduct of dystrophin’s historical legacy.
Therefore, this model suggests that tensile strength-preserving, systemically
deliverable substitutes for full-length dystrophin have the potential to completely
restore normal physiological function, providing opportunities to cure Duchenne
muscular dystrophy despite being significantly shorter than the wt protein.
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Fig. 2.7 Evolution-informed homology modeling of dystrophin spectrin-like
repeats supports an “interlocking chain” model of the dystrophin roddomain. (A) Rod-domain spectrin-like repeat intron position/phase map for
SPTNB2 (a member of the actinin/spectrin protein superfamily), MACF1, and
plectin (another member of the dystroplakin superfamily). Regions of these
proteins used for homology models are indicated: 3EDV (Human Beta2-spectrin
SR4-16) and 5J1G (Human Plectin SR7-8). (B) Phyre2 homology modeling of
dystrophin spectrin repeats 22 and 23 using spectrin repeats from b2-spectrin
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(3EDV) as the homology model template. (C) Homology modeling of dystrophin
spectrin repeats 22 and 23 using spectrin repeats from plectin (5J1G) as the
homology model template. (D) Alternate models of how adjacent spectrin-like
repeats interact within the dystrophin rod-domain.
As an initial test of this approach, we addressed a key question: can
dystrophin and its paralog utrophin be internally truncated in a way that maintains
interactions between natively adjacent triple helical repeats throughout the length
of the shortened rod domain? To this end we engineered a synthetic transgene
named nano4-utrophin (nano4-Utrophin), due to the fact it has four spectrin
repeats, and tested whether it could function to replace dystrophin in the
dystrophin-null mdx mouse model of Duchenne muscular dystrophy. nano4Utrophin was engineered to maximize tensile strength of the novel recombinant
protein by creating a chimeric triple-helical repeat in which half of spectrin repeat
2 is connected to the other half of spectrin repeat 20 (Fig. 2.8A). This allows for
native interactions between spectrin repeat 1 and the front half of spectrin repeat
2, and then the second half of spectrin repeat 20 with the continuing spectrin
repeat 21 (Fig. 2.8A). Therefore, this chimeric repeat forms a continuous,
structurally locked rod domain. Following systemic injection of 1E14 vg/kg AAV9nano4-Utrophin, nano4-Utrophin properly localizes to the sarcolemmal
membrane and restores sarcolemmal localization of the DAPC protein gSarcoglycan, which is lost from the membrane in the absence of dystrophin in the
mdx mouse (Fig. 2.8B) Additionally, nano4-Utrophin prevents central nucleation
in treated mdx muscle, indicating prevention of ongoing muscle regeneration in
the treated muscle (Fig. 2.8B). These data provide evidence that the novel
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chimeric spectrin repeat folds properly and can compensate for dystrophin to
correct the dystrophic phenotype in mdx mice. Importantly, while nano4-Utrophin
accumulates within muscle to the same extent as the previously described
µUtrophin transgene (Song et al., 2019), unlike µUtrophin there is no apparent
fragmentation of nano4-Utrophin visible by western blot (Fig. 2.8C). This
suggests this second-generation nano4-Utrophin transgene may be stronger and
therefore more durable than its first-generation µUtrophin predecessor.
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Figure 2.8 Structurally stabilized, nano4-Utrophin restores Dystrophin
associated protein complex in mdx mice. (A) Structural model of nano4Utrophin. (B) Immunohistochemistry gastrocnemius muscle stained for Utrophin,
g-Sarcoglycan, and wheat germ agglutinin (WGA) which demarcates the muscles
fiber membranes. (C) Western blot showing expression of μUtrophin (Song et al.,
2019) and nano4-Utrophin in quadriceps of 8-week-old mdx mice following
systemic injection of 2.5E12 viral genomes AAV9-nano4-Utrophin or AAV9µUtrophin at 7 days post birth.
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Against the backdrop of phylogeny, a nuanced view of the molecular
evolution of titin and dystrophin suggests a novel synthesis for the impact of
universal physical constraints on organismic form and function. The advent of an
ancestral titin is correlated with the transition from ciliary-to-sarcomeric powered
locomotion, and thereby the transition to scalable locomotion and the
macroevolutionary trend toward increasing body size as observed in the fossil
record (Baker et al., 2015). While titin allowed for the organized assembly of
scalable and powerful contractile sarcomeric units within the 3-dimensional
interior of the cell, dystrophin addressed the inverse of this geometric constraint
at the cellular level: providing a strong yet flexible protein network to enable
power transmission from the three-dimensional cell interior across the twodimensional membrane.

2.4 Materials and Methods

Cnidarians
Ephyra and adult medusa (n=10) Aurelia aurita used for experiments were
randomly selected from a large collection of animals at the Camden Aquarium.
Adult Catostylus mosaicus of different bell diameters (n=3) were randomly
selected from a large collection of animals at the National Aquarium.
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Ephyra whole mount microscopy
Aurelia aurita ephyra were fixed in 10% NBF, permeabilized in 1% Triton X100/PBS solution (Roche Diagnostics GmbH, Mannheim, Germany), and then
incubated with Phalloidin-Alexa fluor 647 (Invitrogen, A22287). Images were
acquired on Zeiss LSM 880 laser-scanning confocal microscope (Zeiss,
Germany).

Cnidarian Immunohistochemistry
Tissue biopsies containing the circular subumbrellar muscles were dissected
from adult medusa jellyfish and fixed in 10% NBF. Fixed tissue was dehydrated
overnight in 30% sucrose solution and then embedded within OCT medium using
liquid nitrogen-cooled isopentane. All the specimens were stored at -80oC. 12 um
sections were cut with a cryostat (MicromTM HM550, Thermo Scientific, USA) at
-25OC, mounted on glass slides (Superfrost Plus, Fisher Scientific, USA), and
stored at -20oC. Immediately prior to use, slides were air dried at room
temperature for 15 minutes and then permeabilized for 20 minutes in 1% Triton
X-100/PBS solution (Roche Diagnostics GmbH, Mannheim, Germany). Sections
were blocked in 5% normal donkey serum before incubation with PhalloidinAlexa fluor 647 (Invitrogen, A22287), anti-ATPB rabbit polyclonal IgG (Abcam,
ab128743), and anti-complex IV subunit I mouse monoclonal IgG2a (Life
Technologies, 1D6E1A8) for 60 minutes at 37OC. Sections were then washed
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and blocked with 10% normal goat serum before incubation with goat anti-mouse
IgG2a-Alexa fluor 594 (Life Technologies, A21135) and Goat anti-rabbit IgGFITC (Invitrogen, 65-6111) for 30 minutes at 37OC. The sections were again
washed with PBS and mounted in Vectashield Mounting Medium (Vector
Laboratories, H-1000) or Vectashield Mounting Medium with DAPI (Vector
Laboratories, H-1500). Images were acquired on Zeiss LSM 880 laser-scanning
confocal microscope (Zeiss, Germany).

RNA-Seq
The reference transcriptome for Nematostella vectensis, was assembled from the
original clustered ESTs published by the JGI genome assembly(Putnam et al.,
2007) along with transcriptomes produced from a clonal lineage originating in
New Jersey, USA, (strain NJ3) generated by the Finnerty Lab [Lubinski, et al., in
revision]. Redundant contigs were removed from the merged assembly using
CD-HIT with a cutoff of 100% sequence identity.

Basic local alignment search tool (BLAST) searches
Genomes were blasted using BLASTp and/or tBLASTn algorithms with pre-set
parameters (BLOSUM62 matrix, expected E value threshold: 10, gap cost
existence: 11, gap cost extension: 1). In cases where full-length homologs were
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not identified, the genomic region surrounding the highest scoring partial-length
hits was downloaded and de novo gene modeling was performed (see gene
modeling methods section). Transcriptomes were blasted from the NCBI BLAST
server using the tBLASTn algorithm against the transcriptome shotgun assembly
(TSA) database, again with pre-set parameters.

Gene Modeling
In the absence of corresponding RNAseq data, protein-coding gene models were
derived from programs of the FGENESH suite (http://www.softberry.com) using
organism-specific gene-finding parameters for the listed organism most closely
related to the species under consideration.

Protein domain analysis
Protein domains were analyzed by running the primary amino acid sequence
against the Pfam, TIGRFAM, CATH-Gene3D, Superfamily, and PIRSF protein
family HMM databases using the European Bioinformatics Institute’s HMMscan
function of the HMMER software package
(http://www.ebi.ac.uk/Tools/hmmer/search/hmmscan)(Finn et al., 2015).

Spectrin Repeat Alignment for Intron Position/Phase Identification
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All Pfam profile-HMM identifiable spectrin repeat domains were aligned to the
Pfam spectrin repeat consensus sequence within HMMscan. These spectrin
repeats were sequentially aligned into a multiple sequence alignment according
to their alignment relative to the consensus sequence.

Intron Position/Phase Identification
ORF annotated cDNA sequences were aligned to their encoding genomic
scaffold using the dot matrix function in MacVector (v15.1) (http://macvector.com)
with 94% sequence identity cut-off. The position and phase of the introns were
identified as breakpoints in the alignment. Each intron position and phase was
confirmed by the presence of consensus splice site donor (-GT) and acceptor
sites (AG-) present within the genomic DNA sequence immediately after and
before each 100% identity aligned block, respectively.

Inferred Ancestral Intron Identification
Inferred ancestral introns are those that are shared between orthologous proteins
in H. sapiens and either A. queenslandica or N. vectensis.

Dot matrices
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cDNA/genomic DNA, protein/genomic DNA, and protein/protein dot matrices
were generated within MacVector (v15.1) (http://macvector.com).

Homology modeling of dystrophin spectrin repeats
Phyre2 was used to model adjacent spectrin repeats from human dystrophin
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) (Kelley et al., 2015).
Distinct homology models were generated using the crystal structure of either
beta2-spectrin (PDB-ID = 3EDV) (Davis et al., 2009) or plectin (PDB-ID = 5J1G)
(Ortega et al., 2016) as the template for the homology model.

Animals- Mice
Murine experiments were executed in compliance with approval from the Animal
Care and Use Committees of the University of Pennsylvania. c57BL/10SnJ and
mdx mice were purchased from the Jackson Laboratory.

AAV9-CMV-nano4-Utrophin vector generation
AAV9 were generated and purified by the University of Pennsylvania preclinical
vector core using the triple transfection method in HEK293 cells as previously
described [Song et al., Nature Medicine, 2019]. Vector preparations were
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assayed for quality, purity, and endotoxin levels before being pooled for injection.
Vector aliquots were stored at -80OC and thawed immediately prior to IM
injection.

Mdx mouse AAV vector administration
C57BL/10 and mdx mice received an intraperitoneal injection of either 1E14
vg/kg (2.5E12 total viral genomes) AAV9-nano4-Utrophin, AAV9-µUtrophin, or
phosphate buffered saline (PBS) at 7 days post birth. Individual mdx pups were
randomly assigned to different treatment vs control groups and investigators
were blinded during all injections and tissue harvesting. All pups were injected
with a total of 50-250 ul PBS as a negative control or AAV9-nano4-Utrophin
diluted in PBS via a 32-gauge insulin syringe. After vector administration, all mice
were returned to their litters and separated after weaning.

Muscle procurement and storage for immunohistochemistry/western blot
Both gastrocnemius muscles were harvested and embedded in O.C.T. (TissueTek, 4583) within 7x7x5 mm base molds (Richard-Allan Scientific, 58949) by
rapid submersion in liquid nitrogen-cooled isopentane. All OCT embedded tissue
blocks were stored at −80°C. 12-24 hours before sectioning, OCT blocks were
moved to -20oC gradually to warm to this temperature for optimal sectioning.
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Cryosections of 10-12 μm thickness were cut on a cryostat (Microm HM550,
Thermo Scientific) at −25 °C and mounted on glass slides (Fisher Scientific,
Superfrost Plus, 12-550-15). Slides were allowed to air dry for 10 minutes at
room temperature before being stored at -20oC.

Murine Immunohistochemistry
10-12 μm gastrocnemius cross-section containing slides were removed from 20oC and allowed to dry at room temperature for 10 minutes. Slides were then
rehydrated for 10 minutes in PBS, permeabilized in 0.1% solution of Triton X-100
diluted in PBS for 10 minutes, and then washed again in PBS for 5 min. Sections
were then blocked with 10% normal donkey serum (Abcam, ab7475, Lot
GR3234297-32) diluted in PBS for 20 minutes at room temperature, followed by
incubation with goat polyclonal a-Utrophin (Santa Cruz, N-19, sc-7460, diluted
1:50 in PBS) and Rabbit anti-γ-sarcoglycan (NBP1-59744, Novus Biologicals,
diluted 1:50 in PBS) for 1 hour at 37oC. Slides were then washed 3x10 minutes in
PBS at RT and again blocked with 10% normal donkey serum (Abcam, ab7475,
Lot GR3234297-32) for 20 minutes at room temperature before being incubated
with PBS containing WGA-555 (Thermo Fisher, W32464, diluted 1:40) and both
donkey a-goat-AF488 and donkey a-rabbit-AF647 (Abcam, ab150061, diluted
1:500) for 30 minutes at 37oC. Following another 3x10 min washes in PBS, slides
were mounted in VECTASHIELD mounting media containing DAPI (Vector
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Laboratories, H-1500). Three 20x images were taken of each muscle section
using a Zeiss Observer 7 widefield microscope (Zeiss).

Western blot
Snap frozen muscles were homogenized in RIPA lysis buffer (Santa Cruz
Biotechnology, sc-24948) supplemented with protease inhibitor cocktail (Roche,
39802300). After homogenization, samples were spun at max speed for 15
minutes at 4oC and the supernatant was then transferred to a new 1.5 ml
microcentrifuge tube. Protein concentration was determined for each sample
using the Pierce BCA protein assay kit (Thermo Scientific, 23227). Samples were
then diluted to an appropriate concentration with 6X Laemmli SDS sample buffer
(Alfa Aesar, J61337) before heat denaturing for 5 minutes at 95oC. 30 g whole
muscle lysate protein was loaded per lane into a 10% SDS-polyacrylamide
Criterion TGX gel (Bio-Rad, 5671034) and run at 80 Volts. Protein was
transferred to a nitrocellulose membrane (Bio-Rad, 1620115) using rapid transfer
buffer (VWR Life Science, N789-4L) according to the manufacturer’s
recommendations. Immediately after transfer, the membrane was washed with
water and then stained for total protein using the REVERT Total Protein Stain Kit
(LI-COR, 926-11010) and imaged by 700 nm fluorescence using the Odyssey Fc
infrared imaging system (LI-COR). The membrane was then blocked for 30
minutes in PBST + 5% BSA solution before being incubated in primary antibody
52

solution overnight at 4oC. Primary antibody solution consisted of PBST + 5%
BSA plus goat polyclonal a-Utrophin (Santa Cruz, N-19, sc-7460). The
membrane was then washed 3x15 minutes in PBST and then incubated in
secondary antibody solution (PBST + 5% BSA + donkey anti-goat-HRP 1:5000)
for one hour at room temperature. The membrane was then washed again 3x15
minutes in PBST before visualizing on the Odyssey Fc imaging system (LI-COR)
using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo
Scientific, 34580).
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CHAPTER 3: T Cell Predominant Response to AAV-Spike
Immunizes Macaques and Protects hACE2 Mice from Lethal
SARS-CoV-2 Pneumonia

The contents of this chapter have been submitted for publication as:
Christopher D. Greer, Coral M. Kasden, Leon Morales, Kendall A. Lundgreen,
Philip D. Hicks, Lilia J. Carpenter, Cristhian Salas-Quinchucua, Elisia D. Tichy,
Albert M. Maguire, Jennifer G. Hoffman, Robin J. Bailey, Shangzhen Zhou,
Angela Luo, Steven J. Chomistek, Benjamin W. Kozyak, Charles R. Bridges,
Gilad S. Gordon, Geoffrey C. Tabin, Paul F. Bates, Jorge E. Osorio, Jean
Bennett, Hansell H. Stedman. T Cell Predominant Response to AAV-Spike
Immunizes Macaques and Protects hACE2 Mice from Lethal SARS-CoV-2
Pneumonia
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3.1 Abstract
Prevention of COVID-19 is widely believed to depend on neutralization of SARSCoV-2 by vaccine-induced humoral immunity, raising concern that emerging
escape variants may perpetuate the pandemic. Here, we demonstrate that a
single intramuscular injection of Adeno-Associated Virus-6 (AAV6) or AAV9
encoding a modified, N-terminal domain deleted spike protein induces robust
cellular immunity and provides long-term protection in k18-hACE2 transgenic
mice from lethal SARS-CoV-2 challenge, associated weight loss and pneumonia
independent of vaccine-induced neutralizing humoral immunity. In both mice and
macaques, vaccine-induced cellular immunity results in the clearance of
transduced muscle fibers coincident with macrophage and CD8+ cytotoxic T cell
infiltration at the site of immunization. Additionally, mice demonstrate a strong
Type-1 polarized cellular immunophenotype and equivalent ex vivo T cell
reactivity to peptides of wt and alpha (B.1.1.7) variant spike. These studies
demonstrate not only that AAV6 and AAV9 can function as effective vaccine
platforms, but also that vaccines can provide long-term efficacy primarily through
the induction of cellular immunity. The findings may provide an alternative
approach to containment of the evolving COVID-19 pandemic and have broader
implications for the development of variant-agnostic universal vaccines against a
wider range of pathogens.
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3.2 Introduction
Spike protein is a class I homotrimeric fusion glycoprotein that initiates viral entry
of host cells via high-affinity engagement of the membrane-bound receptor
angiotensin-converting enzyme 2 (ACE2) (Huang et al., 2020b). Structure-guided
mapping of immunodominant sites elicited by SARS-CoV-2 infection in COVID19 patients has revealed that over 90% of neutralizing humoral responses are
directed against antigenic sites in the ACE2 Receptor Binding Domain (RBD) of
spike (Piccoli et al., 2020). Because of spike’s essential function, it is widely
assumed that vaccine efficacy is tightly linked to titers of measurable neutralizing
antibodies (Erasmus et al., 2020; Sanchez-Felipe et al., 2021). Globally
distributed variants of SARS CoV-2 have mutations that may facilitate escape
from the neutralizing antibodies elicited against the spike protein derived from the
original Wuhan strain (Collier et al., 2021; Faria et al., 2021; Garcia-Beltran et al.,
2021; Planas et al., 2021). However, it has previously been suggested that T cell
immunity alone might be sufficient to prevent COVID-19 based on the
demonstration that cytotoxic CD8 T cells can protect mice from lethal challenge
with mouse-adapted SARS-CoV following infusion of peptide-loaded dendritic
cells (Channappanavar et al., 2014).
Adeno-associated viruses (AAVs) are a class of replication-deficient, nonpathogenic DNA viruses. AAVs have therefore become a preferred vector for
clinical in vivo gene delivery and accordingly were the first vectors approved by
the EMA and FDA for efficient local and systemic gene delivery in human genetic
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disease (Mendell et al., 2017; Morrison, 2015). AAVs have single-stranded
genomes of ~4.8 kb, constraining the use of this vector system to synthetic
genomes of <5kb. Based on our recent demonstration of robust T cell immunity
against an AAV-delivered miniaturized dystrophin transgene in a canine model of
muscular dystrophy (Song et al., 2019), we asked whether such an immune
response to AAV-spike could be sufficient to protect against SARS-CoV-2.

3.3 Results
3.3.1 Design and Characterization of AAV Vaccine
The original Wuhan strain (HB-01) spike protein is encoded by a 3,822nucleotide open reading frame in the RNA genome (Zhou et al., 2020). To
accommodate the powerful and constitutive 832 bp CMV promoter used in our
previous studies(Song et al., 2019), we designed two AAV-deliverable
transgenes encoding mutant spike derivatives that selectively lack the
autonomously folding N-terminal domain (DNTD) (Fig. 3.1A). Both transgenes
contain 8 total mutational sites and are therefore designated “M8” and “M8B,”
with 7 of the 8 mutations being identical between both transgenes. In addition to
two N-terminal deletions (D1 and D2) that together constitute DNTD, both
transgenes share Q271G to afford structural flexibility immediately following D2,
mutated furin and S2’ proteolytic cleavage sites, proline mutations to stabilize
prefusion structure, and deletion of the C-terminal ER-retention signal (D3) (Fig.
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3.1A) (Hoffmann et al., 2020; McBride et al., 2007; McCallum et al., 2020; Ou et
al., 2020; Pallesen et al., 2017; Wrapp et al., 2020). The alternative 8th mutation
was designed to selectively disrupt a conserved epitope encompassing the AA
614 position previously implicated in both antibody-dependent enhancement
(ADE) in SARS-CoV and enhanced transmissibility of SARS-CoV-2 (Hou et al.,
2020; Wang et al., 2016; Yurkovetskiy et al., 2020; Zhou et al., 2021). The
packaged genomes consist of codon-optimized M8 and M8B open reading
frames in an AAV ITR-flanked transcriptional cassette identical to that previously
described (Song et al., 2019) (Fig. 3.1B). We detected robust expression of M8
and M8B by western blot following transfection of HEK293 cells with plasmids
containing the entire AAV-M8 and AAV-M8B genomes (Fig. 3.1C). M8B
expression was additionally observed by immunofluorescent microscopy in
transfected myogenic c2c12 cells (Fig. 3.2).
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Fig. 3.1 AAV vaccine design and characterization. (A) Linear schematic of
mutations and deletions (D’s) present in vaccine candidates M8 and M8B
mapped onto spike protein from SARS-CoV-2 strain Wuhan/IVDC-HB-01/2019.
SS: Signal sequence. NTD: N-Terminal Domain. RBD: Receptor Binding
Domain. TM: Transmembrane Domain. ER: ER Retention Signal. (B) Schematic
depiction of recombinant AAV genome encoding a CMV promoter driven, codonoptimized, truncated spike transgene. (C) Detection of M8 and M8B by western
blot in HEK293 cells transfected with ITR-containing pAAVITRCMV-M8 or M8B
plasmids. Recombinant spike protein was used as a positive control. (D)
Immunohistochemistry of C57BL/10 gastrocnemius muscle 7 days post IM
vaccination of 6.4E10 vg AAV9-M8B (n=2) as well as an unvaccinated negative
control. Wheat germ agglutinin (WGA) demarcates the muscles fiber
membranes.

Fig. 3.2: In vitro characterization of M8B in myogenic cells. c2c12 cells were
lipofectamine transfected with plasmid harboring the following elements in
sequence AAV_ITR-CMV-UTR5’-M8B-3’UTR-pA-AAV_ITR and then grown on
chamber slides. Later cells were fixed and stained for spike protein and nuclei
labeled with DAPI.

3.3.2 Vaccine-Induced Immunity in C57BL/10 Mice
M8B was packaged into AAV9 (AAV9-M8B) and a group of eight C57BL/10 mice
were administered 6.4E10 total viral genomes (vg) by an intramuscular (IM)
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route. Groups of two mice were euthanized at weekly intervals and
immunohistochemistry was performed to assess the timecourse of M8B antigen
expression as well as the overall muscle histology at the site of vaccination. At 7
days post vaccine administration (dpa) there was robust M8B expression within
skeletal muscle fibers, while the muscle histology was otherwise normal (Fig.
1D). This finding remained unchanged until 21 dpa when regions of dense
mononuclear infiltrates surrounded M8B-expressing muscle fibers.
Immunohistological staining revealed F4/80+ macrophages (Fig. 3.3A) and
CD8+ cytotoxic T cells (Fig. 3.3B) were present within the mononuclear infiltrates
(Fig. 3.3, A and B, inserts), indicating an ongoing cellular immune response
targeting the transduced muscle fibers. Actively regenerating, centrally nucleated
muscle fibers resembling those in murine muscular dystrophy are seen near
infiltrating immune cells, further suggesting immune-mediated elimination of
transduced muscle fibers (Song et al., 2019) (Fig. 3.3B arrows). To control for
immune response directed against the AAV9 vector capsid, we injected
C57BL/10 mice with 6.4E10 vg AAV9-µUtrophin, a non-immunogenic vector in
development for treatment of Duchenne muscular dystrophy (Song et al., 2019).
At 21 dpa we observed the absence of macrophage or cytotoxic T cell infiltration,
despite intense focal expression of the non-immunogenic µUtrophin transgene
product (Fig. 3.4).
To characterize the T cell responses, C57BL/10 mice received a single IM
administration of either 6.4E10 vg AAV9-M8, AAV9-M8B, or AAV6-M8B and
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splenocytes were harvested one month post administration (mpa). Following ex
vivo stimulation with peptide pools spanning the S1 and S2 fragment of spike,
enzyme-linked immune absorbent spot (ELISpot) assays demonstrated many
IFNg-secreting cells in all vaccine groups (Fig. 3.3C), evidence of a strong Type1 T cell response. These data indicate that a single IM dose of AAV-encoding
either M8 or M8B can elicit a robust T cell mediated immune response against
the AAV-encoded transgene product in vivo.
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Fig. 3.3. AAV Vaccine-Induced Cellular Immunogenicity in Mice. IHC shows
F4/80+ macrophage (A) and CD8+ cytotoxic T-cell (B) infiltration surrounding
M8B expressing muscle fibers at 21 dpa AAV9-M8B (n=2). Scale bar =100um.
(C) C57BL/10 mice received 6.4E10 vg IM injection of either AAV9-M8, AAV9M8B, AAV6-M8B, or AAV buffer (PBS + 0.001% PF68) as a mock vaccinated
control. At one month post vaccination, the indicated number of IFNg secreting
cells per 1E6 splenocytes were detected by ELISpot in response to ex vivo
stimulation with peptide pools spanning both the S1 and S2 fragment of WT HB01 spike. (D-G) Mixed gender 2–3-month-old mice received either 1E12 vg
AAV6-M8B (n=5 k18-hACE2 mice) or AAV buffer (n=2 k18-hACE2, n=3
C57BL/10). At 65 days post vaccination, the indicated number of IFNg (D), IL-2
(E), IL-4 (F), and IL-10 (G) secreting cells per 1E6 splenocytes were detected by
ELISpot. Alpha variant spike peptide pools were used in (D) where indicated. (CG) Symbols represent individual animals. Lines show mean +/- 1 S.D. Results
were compared either by Brown–Forsythe and Welch’s analysis of variance
(ANOVA) with Dunnett’s T3 multiple comparisons test (C and D) or Welch’s t-test
(E-G).
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Fig. 3.4 AAV vaccine immunogenicity is directed against spike transgene.
F4/80+ macrophages (A) and CD8+ cytotoxic T-cells (B) fail to infiltrate and
surround µUtrophin expressing muscle fibers at 3 weeks post 50 ul IM injection of
6.4E10 vg. AAV9-µUtrophin.

3.3.3 Protection and Immunity in k18-hACE2 Mice
Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 in
humans (Zhou et al., 2020). Wild type mice are not susceptible to SARS-CoV-2
infection because the spike RBD has low affinity to the mouse ACE2 ortholog.
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k18-hACE2 transgenic mice express human ACE2 (hACE2) driven by the
cytokeratin 18 (k18) promoter in airway and other epithelial cells (Zheng et al.,
2021). It was recently demonstrated that inoculation of this strain with 10^4
plaque-forming units (PFU) generates 50% lethal respiratory disease resembling
severe COVID-19 (Winkler et al., 2020; Zheng et al., 2021).
To characterize the vaccine-induced memory response in k18-hACE2
mice, animals received a single IM injection of either 1E12 vg AAV6-M8B or AAV
buffer and splenocytes were harvested at 65 dpa. ELISpot revealed significant
numbers of splenocytes secreted T-helper-1 (Th1)-type cytokines IFNg and IL-2
upon ex vivo stimulation with peptide pools spanning the S1 and S2 fragment of
spike (Fig. 3.3, D and E). Interestingly, at 65 dpa there is no significant increase
in number of splenocytes secreting the canonical T-helper-2 (Th2)-type cytokine
IL-4 upon identical ex vivo stimulation (Fig. 3.3F); however, a significant, albeit
very small total number of cells secrete IL-10 (Fig. 3.3G). Finally, to assess
whether T cell responses are maintained in response to exposure to spike
proteins from variant SARS-CoV-2 strains, we ran a second IFNg ELISpot and
stimulated ex vivo with peptide pools spanning the S1 and S2 fragments of spike
protein of the alpha variant and there was no change in the number of IFNg
secreting splenocytes (Fig. 3.3D). Together, these experiments indicate that the
cellular memory response against the spike is strongly Type-1 polarized, and this
response is not diminished by mutations present in the alpha variant spike.
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To assess vaccine efficacy against lethal SARS-CoV-2 challenge and
associated viral pneumonia, 6–8-week-old k18-hACE2 mice were administered a
single dose IM injection of either 1E12 vg AAV9-M8, AAV9-M8B, AAV6-M8B, or
AAV buffer as a mock vaccinated control group before intranasal inoculation with
a lethal dose of 2.5x10^4 PFU of SARS-CoV-2 at 25 dpa (Fig. 3.5A). To
compare tissues and viral RNA levels between groups, we decided before the
study was initiated to terminate the experiment at 7 days post infection (dpi) with
SARS-CoV-2, by which time most k18-hACE2 mice will have died or met
objective criteria for euthanasia by the masked/blinded veterinarians overseeing
the challenge experiments. As expected, by 6 dpi 100% of mock-vaccinated
animals met terminal euthanasia criteria as determined by the presence of all of
the following clinical findings: absence of movement, persistent eye closure with
palpebral crusting, nasal secretions, kyphosis, and the presence of a rough coat
resembling mice with the “rc” mutation (Cao et al., 2007). No vaccinated animal
demonstrated any of these clinical symptoms at any point in the 7-day
experiment (Fig. 3.5B).
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Fig. 3.5 Protection and efficacy in k18-hACE2 mice. (A) Experimental
schematic for data depicted in Fig. 3A-G and Fig. 3.6. (B) Kaplan Meier survival
curve. (C) Individual animal weight traces for each animal following 2.5E4 PFU
SARS-CoV-2 IN inoculation. (D) Individual results of the 8-minute treadmill
performance test depicted in Fig. 3.6B. Because there is a maximum
performance on the time restricted protocol, if multiple animals achieve a
maximal distance, they appear on top of each other. All animals are represented
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in the graphic. (E) Lung IHC post SARS-CoV-2 challenge of mice depicted in the
schematic in (A) for spike protein, WGA (extracellular matrix stain to assess
gross lung morphology), and DAPI. (C and D) Circles represent females and
squares represent males.

Fig. 3.6 AAV-M8/M8B protects transgenic k18-hACE2 mice from lethal
SARS-CoV-2 challenge and associated severe disease. k18-hACE2 mice
received an IM injection of either 1E12 vg AAV6-M8B (n=5), 1E12 vg AAV9-M8B
(n=5), 1E12 AAV9-M8 (n=5), or AAV formulation buffer (n=5) as a mock
vaccination control. (A) Weight trace post challenge. Groups were compared by
two-way ANOVA with Dunnett’s multiple comparisons test. p-values shown in
figure are at 6 dpi compared to mock. At 5 dpi, p<0.01 for AAV9-M8b and
p<0.001 for AAV6-M8B and AAV9-M8. (B) Results of a treadmill performance
test at 5 dpi, as measured by distance traveled in 8 min. (C and D) Results of the
respiratory assessment at both 5 and 6 dpi, as measured by tidal volume (C) and
respiratory rate (D). Days 5 and 6 were independently compared by Brown–
Forsythe and Welch’s analysis of variance (ANOVA) with Dunnett’s T3 multiple
comparisons test. (E) Representative lung histopathology. Scale bar=100um. (F)
Viral RNA quantified from whole lung homogenates. (G) Anti-Spike RBD IgG
titers determined by ELISA following viral challenge compared to a group of 1E12
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vg AAV6-M8B vaccinated, but unchallenged mice (n=6) at the equivalent
timepoint post-vaccination. (H) SARS-CoV-2 neutralizing antibody titers
determined by focus reduction neutralization test (FRNT50). This was similarly
compared to the unchallenged AAV6-M8B vaccinated group as in (G). (I) Kaplan
Meier curve depicting aggregate survival for all unvaccinated and 1E12 vg AAV
vaccinated k18-hACE2 mice post infection with 2.5E4 PFU SARS-CoV-2 (AAV6M8B n=15, AAV9-M8B n=5, AAV9-M8 n=5). Data generated from 3 independent
experiments. Survival was compared by the log-ranked Mantel-Cox test. (B-D)
Each shape indicates an individual mouse, and the lines show the mean +/- 1
S.D. (G) Symbols represent the geometric mean for all replicates of an individual
animal. (F-H) The dotted line indicates the limit of detection, and the lines show
the mean +/- 1 S.D. and groups were compared by Kruskal–Wallis analysis of
variance (ANOVA) with Dunn’s multiple comparisons test.

While the experimental design (termination at 7 dpi) did not allow for a
longer assessment of differential survival, it did permit assessment of other
objective surrogates of vaccine-induced protection. Mock-vaccinated mice began
progressively losing weight starting at 4 dpi whereas animals in the vaccinated
groups maintained stable weight over the 7 days post challenge (Fig. 3.5C, Fig.
3.6A). Animals were assessed for cardiopulmonary performance at 5 dpi by
measuring the distance they were able to run on a treadmill for 8 minutes
according to a predetermined ramping protocol. Whereas 80% of the mock
vaccinated mice performed worse on the treadmill at 5 dpi than they did a week
prior to viral challenge, all mice in each vaccinated group either improved or had
no change in performance (Fig. 3.5D, Fig. 3.6B). Respiratory performance of
these animals was assessed by whole body plethysmography at 5 and 6 dpi and
there was a significant drop off in both tidal volume and respiratory rate in the
mock vaccinated group at each of these time points relative to the pre-challenge
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assessment of all k18-hACE2 mice (Fig. 3.6, C and D). Consistent with the
observed differences in exercise tolerance and respiration, lungs of AAV-injected
mice appeared grossly normal, while lungs of PBS-injected mice revealed signs
of severe interstitial pneumonia characterized
by collapse of the alveolar spaces (Fig.
3.6E). We quantified viral RNA present in the
lungs and observed a 2.9-log reduction for
AAV9-M8B, a 4.4-log reduction for AAV9-M8,
and a 4.3-log reduction for AA6-M8B
vaccinated relative to the mock-vaccinated
control group (Fig. 3.6F), consistent with the
significant decrease in spike protein in lung
tissue sections by immunohistochemistry
(Fig. 3.5E).
Interestingly, our analysis of serum
obtained at necropsy revealed that this robust
protection occurred despite the absence of
vaccine-induced neutralizing humoral
immunity (Fig. 3.6G). This finding was
confirmed in mice by giving either AAV9-M8
or AAV9-M8B followed by a booster 5 weeks
later. Three weeks post booster there was
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Fig. 3.7 Boosting fails to elicit
neutralizing humoral
immunity following booster
vaccination. 2–5-month-old
C57BL/10 mice received
6.4E10 vg IM injection of either
AAV9-M8 (n=5) or AAV9-M8B
(n=3) and then received an
identical booster vaccination 5
weeks later. Three weeks after
the booster dose animals were
evaluated for the presence of
SARS-CoV-2 neutralizing
antibodies. Data is reported as
log10(inverse SARS-CoV-2 50%
pseudovirus-neutralization titer
as measured by focus reduction
neutralization test (FRNT50)).

still an absence of detectable neutralizing antibody (Fig. 3.7). However, to
support the claim AAV-M8B-primed CD4+ T cells enhance the kinetics of
neutralizing antibody production post-SARS-CoV-2 infection, we show that
neutralizing antibodies in the challenged AAV6-M8B and AAV9-M8B groups, but
not the challenged mock vaccinated group, are significantly elevated relative to
the unchallenged AAV6-M8B vaccinated group at the completion of the
experiment (Fig 3.6G). To further support the claim of accelerated postvaccination, post-infection humoral immunity kinetics, we assayed for IgG titers
against recombinant spike RBD. Some of the unchallenged AAV6-M8B group did
have detectable, albeit low levels, of anti-RBD IgG whereas all the challenged
mock vaccinated animals were below the limit of detection (Fig. 3.6H). However,
the challenged AAV6-M8B and AAV9-M8B vaccinated mice were elevated 6.6fold and 14.3-fold, respectively, relative to the unchallenged AAV6-M8B group
and the challenged AAV9-M8B groups RBD IgG titer was significantly greater
than that of the challenged mock vaccinated group (Fig. 3.6H). Together, these
serological studies reveal that AAV-M8/M8B vaccination alone produces a very
mild humoral immune response with no detectable neutralizing antibody
component; however, upon infection vaccinated mice respond with an
accelerated humoral response.
We next assessed long-term therapeutic efficacy as well as vaccine
stability in real-world storage conditions, specifically following long-term
refrigeration. A cryofrozen vial of AAV6-M8B was thawed and used to vaccinate
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k18-hACE2 mice (Cohort 1). The AAV6-M8B vial was then stored at 4oC for 4
months before being used to vaccinate a second group of k18-hACE2 mice
(Cohort 2) and then both cohorts were simultaneously challenged with 2.5x10^4
PFU SARS-CoV-2 IN ~18 days later (Fig. 3.8A). We observed long-term
protection from lethality and weight loss 4.5 months out from single dose
vaccination in Cohort 1 (Fig. 3.8, B-D). Furthermore, long-term refrigeration did
not impair its ability to protect against lethal challenge in Cohort 2 even at only 18
dpa (Fig. 3.8E); however, protection against weight loss was not statistically
significant at this early timepoint post vaccination (Fig. 3.8, F and G).
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Fig. 3.8 Long term efficacy studies of AAV6-M8B in k18-hACE2 mice. (A)
Schematic of experimental plan. A vial of vector was thawed and immediately
used to vaccinate “cohort 1” of k18-hACE2 mice (n=5 AAV6-M8B, n=5 mock).
The tube was then kept in at 4oC for >4 months before it was used to vaccinate a
second cohort, “cohort 2,” of k18-hACE2 mice (n=5 AAV6-M8B, n=6 mock). Both
cohorts were challenged days apart from each other with IN inoculation of 2.5E4
PFU SARS-CoV-2, at 4.5 mpv for cohort 1 (B-D) and at 18 dpv for cohort 2 (EG). All animals were tracked until a terminal concluding date. (B and E) Kaplan
Meier survival curve post SARS-CoV-2 infection. Survival was compared by the
log-ranked Mantel-Cox test. (C and F) Change in body weight post SARS-CoV-2
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infection. Weight was compared by the nonparametric Mann–Whitney U-test.
The average mock vaccinated body weight in (F) switches from red to blue when
the entire average weight is derived from a single surviving animal. (D and G)
Are the individual animal traces for the animals averaged in (C and F).

In aggregate, these challenge experiments demonstrate that vaccination
with AAV-M8/M8B provides a highly significant survival advantage to k18-hACE2
mice upon subsequent lethal challenge with SARS-CoV-2 (Fig. 3.6I).

3.3.4 Vaccine-Induced Immunity in Macaques
To preliminarily assess capsid efficacy and dose-response in non-human
primates, four cynomolgus macaques were vaccinated IM with either AAV6-M8B
or AAV9-M8B at a dose of either 1E11 vg or 1E12 vg. At 29 dpa there is
significant mononuclear cell infiltration and the presence of cytotoxic CD8 T cells
and CD11b+ macrophages surrounding M8B expressing muscle fibers (Fig. 3.9,
A and B). IFNg ELISpots performed on peripheral blood mononuclear cells
(PBMCs) isolated at 29 dpa demonstrated the presence of spike antigen-specific
T cells in both macaques that received the higher dose of 1E12 vg, but neither
animal that received the lower dose of 1E11 vg (Fig. 3.9C). Finally, as observed
in mice, there was a small increase in the anti-Spike-ECD IgG titers of both
macaques that received the 1E12 vg dose, but neither animal that received the
dose of 1E11 vg and no vaccine-induced neutralizing antibodies were detectable
at 29 dpa at any dose (Fig. 3.9, D and E). These data strongly support our data
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generated from mice and suggest a similar immune response to AAV-M8B in
primates.

Fig. 3.9 AAV Vaccine Immunogenicity in Macaques. (A) IHC shows CD8+
cytotoxic T cell infiltration surrounding M8B expressing muscle fibers 29 days
after a single IM vaccination with either 1E12 vg of AAV6-M8B or AAV9-M8B. (B)
IHC shows CD11b+ macrophages in the areas nearby CD8+ cytotoxic T cells
surrounding muscle fibers following IM vaccination. (C) Number of IFNg secreting
cells per 1E6 PBMCs as detected by ELISpot. (D) Anti-Spike ECD IgG titers
determined by ELISA. (E) SARS-CoV-2 neutralizing antibody titers determined
by focus reduction neutralization test (FRNT50).
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3.4 DISCUSSION
Here we have shown that AAV vectors encoding N-terminally deleted spike
proteins can induce robust, long-term protection of k18-hACE2 mice from lethal
SARS-CoV-2 challenge as well as associated viral pneumonia. This protection in
mice was mediated by a Type 1-polarized cellular immune response in the
absence of a detectable neutralizing humoral immune response. We have also
demonstrated that AAV vaccines remain effective even after months of standard
refrigeration and are effective and durable following single dose administration.
These features make the vaccine platform potentially advantageous for
distribution to rural, sparsely populated, or resource-limited regions where longterm vaccine thermostability may be critical.
Interestingly, the observed protection against viral challenge occurred in
the absence of vaccine-induced neutralizing antibodies, thereby formally
demonstrating that neutralizing humoral immunity is not a prerequisite for
protection against SARS-CoV-2 infection. In addition to providing immediate
protection against viral replication in host cells, strong and durable T cell memory
in recipients of an AAV-M8/M8B vaccine would be expected to accelerate affinity
maturation of neutralizing antibodies specific for a mutant RBD in any SARSCoV-2 variant to which the host is initially exposed. Our findings regarding
similar T cell reactivity to peptides from the alpha variant illustrate an example of
such preservation of effector and helper T cell responses. A theoretical
advantage of this variant-agnostic approach for a vaccinated population is its
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potential to circumvent the downside of antigenic imprinting to RBD
conformational epitopes specific to the original Wuhan SARS-CoV-2 Spike.
Among individuals in an outbred human population, the identity of
immunodominant T cell epitopes will vary widely across the Spike sequence
based on HLA polymorphism, in contrast to the focal concentration of
conformational B cell epitopes in the RBD to which most individuals must target
neutralizing antibodies. Thus, the strength and durability of vaccine-induced T
cell immunity has important implications for the future evolution of the COVID-19
pandemic as herd immunity to the original variant escalates and selective
pressure builds for SARS-CoV-2 variants capable of escaping neutralizing
humoral immunity through mutations in the RBD.

3.5 MATERIALS AND METHODS
Study design
The objective of this study was to determine the immunogenicity of an AAVdeliverable spike vaccine in mice and non-human primates. Once the safety and
immunogenicity of the vaccine was demonstrated, we sought to demonstrate the
efficacy of the vaccine from preventing SARS-CoV-2 pneumonia and death in the
k18-hACE2 mouse model. All SARS-CoV-2 intranasal inoculations of k18-hACE2
mice and subsequent physiological assessments and monitoring were done
blinded to animal vaccination status. This was achieved by animals being
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vaccinated (or mock vaccinated) at University of Pennsylvania, but then
challenged with SARS-CoV-2 and assessed by a different team at University of
Wisconsin, Madison with their only identifier being an ear tag. No statistical
method was used to predetermine sample size for murine studies and the nonhuman primate sample size was restricted by the number of available animals.
For all murine challenge studies, groups were composed of equal numbers of
males and females or when n=5 genders within groups were randomized with
either 2 males/3 females, or the inverse. End points were selected prior to the
start of each study based on the specific primary objective of the study.

M8/M8B transgene synthesis
De novo gene synthesis of M8 and M8B cDNA was performed by GeneArt using
the codon optimization scheme from (Sino Biological, VG40589-UT). M8/M8B
were cloned into the AAV transfer plasmid pZac2.1 along with (or flanked by) a
CMV promoter and SV40 PolyA sequence. Cloned plasmids were transformed
into Stbl2 competent cells and selected by ampicillin resistance.

AAV6/9 vector generation
AAV6 and AAV9 were individually generated and purified by the University of
Pennsylvania preclinical vector core using the triple transfection method in
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HEK293 cells as previously described(Song et al., 2019). Vector preparations
were assayed for quality, purity, and endotoxin levels. Vector aliquots were
stored at -80oC and thawed immediately prior to IM injection, except where
explicitly stated for experimental purposes.

Transfection and Immunocytochemistry of C2C12 cells
3.0E4 C2C12 cells were plated into each well of an 8 well chamber slide
(Millipore, PEZGS0816) and cultured for 24 hours in growth media (DMEM high
glucose supplemented with 10% FBS, 1x anti-anti, 1x GlutaMAX, 1x NEAA).
Cells were then transfected with 0.4 ug plasmid DNA using lipofectamine 3000 in
growth media for 5 hours at 37oC before being switched to C2C12 differentiation
medium (DMDM high glucose, 5% horse serum, 1x anti-anti, 1x NEAA, 1x
glutamax) for 72 hours. Cells were then fixed with 10% NBF for 10 min at room
temperature and then washed for 5 minutes with PBS before being
permeabilized in 0.5% Triton X-100 solution 10 minutes at room temp. Cells were
washed in PBS for 5 min before being blocked with 10% normal donkey serum
(Abcam, ab7475, Lot GR3234297-32) diluted in PBS for 20 minutes at room
temperature, followed by incubation with rabbit polyclonal anti-SARS-CoV-2
Spike/RBD (Sino 40592-T62, Lot HD14AU0606 diluted 1:50 in PBS) for 1 hour at
37oC. Slides were then washed 3x10 minutes in PBS at RT and again blocked
with 10% normal donkey serum (Abcam, ab7475, Lot GR3234297-32) for 20
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minutes at room temperature before being incubated with PBS containing both
WGA-555 (Thermo Fisher, W32464, diluted 1:40) and donkey anti-rabbit-AF488
(Abcam, ab150061, diluted 1:500) for 30 minutes at 37oC. Following another
3x10 min washes in PBS, slides were mounted in VECTASHIELD mounting
media containing DAPI (Vector Laboratories, H-1500). Images were taken using
a Zeiss Observer 7 widefield microscope (Zeiss).

Western Blot of transfected HEK293
M8/M8B-pZac2.1 plasmid transfected HEK293 cell pellets were lysed in RIPA
lysis buffer (Santa Cruz Biotechnology, sc-24948) supplemented with protease
inhibitor cocktail (Roche, 39802300). After homogenization, samples were spun
at max speed for 15 minutes at 4oC and the supernatant was then transferred to
a new 1.5 ml microcentrifuge tube. Protein concentration was determined for
each sample using the Pierce BCA protein assay kit (Thermo Scientific, 23227).
Samples were then diluted to an appropriate concentration with 6X Laemmli SDS
sample buffer (Alfa Aesar, J61337) before heat denaturing for 5 minutes at 95oC.
30 ug total protein was loaded per lane after transfer to a nitrocellulose
membrane total protein was imaged for loading control using the REVERT Total
Protein Stain Kit (LI-COR, 926-11010) and imaged by 700 nm fluorescence using
the Odyssey Fc infrared imaging system (LI-COR). The membrane was then
stained overnight at 4o in PBST + 5% BSA containing anti-SARS-CoV-2
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Spike/RBD (Sino 40592-T62, Lot HD14AU0606 diluted 1:1500). The membrane
was then washed 3x15 minutes in PBST and then incubated in secondary
antibody solution (PBST + 5% BSA + Goat anti-Rabbit-HRP 1:5000) (Abcam,
ab205718) for one hour at room temperature. The membrane was then washed
again 3x15 minutes in PBST before visualizing on the Odyssey Fc imaging
system (LI-COR) using SuperSignal West Pico PLUS Chemiluminescent
Substrate (Thermo Scientific, 34580).

Mice
Murine experiments were executed in compliance with approval from the Animal
Care and Use Committees of the University of Pennsylvania and University of
Wisconsin at Madison. c57BL/10SnJ and B6.Cg-Tg(K18-ACE2)2Prlmn/J mice
were purchased from the Jackson Laboratory.

Vaccination of c57BL/10 and k18-hACE2 mice
Immediately prior to IM injection, the AAV was removed from the -80oC freezer
and thawed at room temperature. The AAV vector was then diluted in formulation
buffer (PBS + 0.001% Pluronic F-68) such that 50 ul of diluted vector contained
the desired dose of viral genomes (either 6.4E10 or 1E12 vg), this controlled for
volume injected across either dose administered. Mixed gender 2-5-month-old
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C57BL/10 mice or 6–9-week-old k18-hACE2 mice were randomly assigned to
groups and anesthetized with isoflurane before receiving an intra gastrocnemius
injection of either 50 ul AAV or 50 ul formulation buffer using a custom 100 uL
Hamilton syringe with a 32-gauge needle (475-41182, Lot 81008). Additionally,
k18-hACE2 mice were ear tagged as to keep the team performing the challenge
experiments blinded to the animal’s treatment status.

c57BL/10 muscle procurement, sectioning, and storage for
immunohistochemistry
At pre-determined timepoints post-vaccination, mice were anesthetized with 4%
isoflurane in an anesthesia chamber before being transferred to a nose cone
where they were maintained on 4% isoflurane in 100% O2 at a flow rate of 1
L/minute. Toe pinch was performed to ensure mice were deeply anesthetized
before mice were euthanized by cervical dislocation. Gastrocnemius muscles
were harvested and embedded in O.C.T. (Tissue-Tek, 4583) within 7x7x5 mm
base molds (Richard-Allan Scientific, 58949) by rapid submersion in liquid
nitrogen-cooled isopentane. All OCT embedded tissue blocks were stored at −80
°C. 12-24 hours before sectioning, OCT blocks were moved to -20oC to gradually
to warm to this temperature for optimal sectioning. Cryosections of 10-12 μm
thickness were cut on a cryostat (Microm HM550, Thermo Scientific) at −22 °C
and mounted on glass slides (Fisher Scientific, Superfrost Plus, 12-550-15).
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Slides were allowed to air dry for 10 minutes at room temperature before being
stored at -20oC.

c57BL/10 Immunohistochemistry
10-12 μm gastrocnemius cross-section containing slides were removed from 20oC and allowed to dry at room temperature for 10 minutes. Slides were then
rehydrated for 10 minutes in PBS, permeabilized in 0.1% solution of Triton X-100
diluted in PBS for 10 minutes, and then washed again in PBS for 5 min. Sections
were then blocked with 10% normal donkey serum (Abcam, ab7475, Lot
GR3234297-32) diluted in PBS for 20 minutes at room temperature, followed by
incubation with either rabbit polyclonal anti-Utrophin (custom, Sigma) or rabbit
polyclonal anti-SARS-CoV-2 Spike/RBD (Sino, 40592-T62), with or without rat
anti-CD8 (Thermo Fisher, MA5-17594) or rat anti-F4/80 (Thermo Fisher, MA191124), for 1 hour at 37oC. Slides were then washed 3x10 minutes in PBS at RT
and again blocked with 10% normal donkey serum (Abcam, ab7475, Lot
GR3234297-32) for 20 minutes at room temperature before being incubated with
PBS containing WGA-555 (Thermo Fisher, W32464), donkey anti-rabbit-AF488
(Abcam, ab150061), and donkey anti-rat-AF647 (Abcam, ab150155) for 30
minutes at 37oC. Following another 3x10 min washes in PBS, slides were
mounted in VECTASHIELD mounting media containing DAPI (Vector
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Laboratories, H-1500). Images were taken using a Zeiss Observer 7 widefield
microscope (Zeiss).

SARS-CoV-2 Viral stock
SARS-CoV-2 strain USA-WA1/2020 was provided by BEI (NR-52281),
propagation was performed by passaging two times in Vero E6 cells in DMEM
supplemented with 2% fetal bovine serum and 1x Antibiotic Antimycotic Solution
(sigma A5955). Supernatant was collected upon observation of cytopathic effect
and centrifuged for debris removal. Titration was performed in triplicate by plaque
assay in 6 well plates with crystal violet dye using a 200µL inoculum per well
from the generated stock. The produced stock with a final titer of 3x106 PFU/ml
was aliquoted and stored at -80°C.

SARS-CoV-2 Challenge
Infection of mice was conducted in a certified Animal Biosafety Level 3 (ABSL-3)
laboratory at University of Wisconsin - Madison. The protocol for the challenge
studies was approved by the University of Wisconsin Institutional Animal Care
and Use Committee (Protocol Number V006324). Animals were anesthetized
with 5% isoflurane, and 2.5x104 PFU of SARS-CoV-2 (USA-WA1/2020) in a 50µL
volume was administered via Intranasal inoculation using a micropipette tip. On
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the day of challenge and each day after animals were weighed and monitored for
health issues, loss of weight, inappetence, activity reduction, and respiratory
distress. Animals were euthanized by exposing them to an overdose of isoflurane
in a closed chamber followed by cervical dislocation at the completion of the
experiment or when presented with the following predetermined human endpoint
criteria-- loss of greater than 20% body weight or the presence of all the following
clinical signs: respiratory distress, inappetence, signs of dehydration, lack of
mobility and critical body condition. Before euthanasia, blood serum was
obtained by maxillary vein collection. After euthanasia, right lung for viral loads
were collected, weighed, and homogenized in 1 mL of Trizol using a bead beater,
after centrifugation, supernatant was stored at -80°C. Left lung was separated
and inflated with 10% neutral buffered formalin using a 26G veterinary I.V.
catheter and preserved in the formalin for histopathological changes evaluation.

Treadmill acclimatization and performance assessment
Vaccinated and mock vaccinated k18-hACE2 mice were acclimated to treadmill
twice prior to assessing their 8-minute treadmill performance 6 days before
SARS-CoV-2 infection. These same mice were then assessed according to the
same performance test at 5 days post SARS-CoV-2 infection. Treadmill
performance tests followed a sex specific, 8-minute speed ramping protocol and
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the distance recorded was either that maximally allowed by the protocol in 8minutes or that which they had completed upon their fifth 1.2 mA electrical shock.

Whole body plethysmography
A custom whole body plethysmography system was designed for use in the
ABSL3 facility at the University of Wisconsin to minimize both the need for
mouse handling and the potential for mouse-to-mouse SARS-CoV-2
contamination. Pressure deflections in 500 cc single-use chambers were
recorded into Acqknowledge 4.2 files using the Biopac TSD160A, DA100C,
UIM100A, ad MP150 hardware modules in series. The DA100C module was
configured to the following settings: GAIN 1000, 10HzLP ON, LP 5kHz, and HP
0.05Hz. Investigators blinded to group assignments recorded ear tag number of
individual mice and then placed them into a chamber to enable a 60 second
period of uninterrupted pressure recording. To minimize background noise, the
raw signal collected was filtered via Acqknowledge 4.2 Software using the
following settings: Low Pass sample rate at 8Hz, High Pass sample rate at
1.5Hz. Rate Signal parameter and identification of Peaks was determined using a
threshold of 0.002 Volts. All files were then managed identically to enable
extraction of average values and standard deviations for two parameters over 60
seconds: respiratory rate and amplitude, the latter proportional to relative tidal
volume. The results for individual mice were normalized to baseline data
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obtained before inoculation with SARS-CoV-2. The sensitivity and specificity of
the system was validated in mice recovering from inhalational general anesthesia
using brief exposure to isoflurane at 4% of inspired gas.

Lung Histology
Left lung tissues were fixed in 10% neutral buffered formalin then paraffinembedded and sectioned at 7um. Sections were deparaffinized in two changes
of xylene followed by rehydration through descending concentrations of ethanol
(100%, 95%, 80%, water). Sections were stained in Gill’s hematoxylin (Thermo
Scientific Cat# 72604) for 3 minutes, then rinsed under running tap water,
differentiated in 0.1% acetic acid for 3 seconds, followed by a second rinse.
Sections were then immersed in Scott’s bluing reagent (Ricca Cat# 6697-1) for 1
minute and transferred to water, then counterstained in eosin-Y solution (Thermo
Fisher Cat# 71204) for 30 seconds. Finally, slides were dehydrated from water
through ascending concentration of ethanol (70%, 95%, two changes 100%),
cleared in two changes of xylene, and mounted with Cytoseal 60 (Thermo
Scientific Cat# 8310-4) and coverslip. Sections were visualized by brightfield
microscopy.

SARS-CoV-2 viral load quantification
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RNA was extracted from tissue homogenates using a Trizol/chloroform extraction
method, and cDNA was synthesized using high-capacity cDNA to RNA-to-cDNA
Kit (Thermo Scientific). SARS-CoV-2 RNA levels were measured by quantitative
PCR using TaqMan Fast Universal PCR Master Mix (Thermo Fisher: Cat#
4352042) on the Applied Biosystems 7500 Fast Dx Real-Time PCR System.
SARS-CoV-2-specific primers and probe set from the CDC 2019-Novel
Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel were used to
target the SARS-CoV-2 nucleocapsid (IDT: Cat.# 10006713). CoV_N1 F Primer:
GACCCCAAAATCAGCGAAAT; CoV_N1 R primer:
TCTGGTTACTGCCAGTTGAATCTG; CoV_N1 probe: FAMACCCCGCATTACGTTTGGTGGACC-BHQ1. A standard curve was generated
with SARS-CoV-2 nCov_N_Positive control plasmid (IDT: Cat. #10006625) to
determine viral copy numbers. Viral gene expression levels were normalized to
lung tissue weight.

SARS-CoV-2 Neutralization Assay
Production of VSV pseudotyped with SARS-CoV-2 S: 293T cells plated 24
hours previously at 5 X 106 cells per 10 cm dish were transfected using calcium
phosphate with 35 μg of pCG1 SARS-CoV-2 S D614G delta18 expression
plasmid encoding a codon optimized SARS-CoV2 S gene with an 18-residue
truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann). Twelve
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hours post transfection the cells were fed with fresh media containing 5mM
sodium butyrate to increase expression of the transfected DNA. Thirty hours after
transfection, the SARS-CoV-2 spike expressing cells were infected for 2-4 hours
with VSV-G pseudotyped VSVΔG-RFP at an MOI of ~1-3. After infection, the
cells were washed twice with media to remove unbound virus. Media containing
the VSVΔG-RFP SARS-CoV-2 pseudotypes was harvested 28-30 hours after
infection and clarified by centrifugation twice at 6000g then aliquoted and stored
at -80 °C until used for antibody neutralization analysis.

Antibody neutralization assay using VSVΔG-RFP SARS-CoV-2: All sera were
heat-inactivated for 30 minutes at 55 ⁰C prior to use in neutralization assay. Vero
E6 cells stably expressing TMPRSS2 were seeded in 100 μl at 2.5x104 cells/well
in a 96 well collagen coated plate. The next day, 2-fold serially diluted serum
samples were mixed with VSVΔG-RFP SARS-CoV-2 pseudotype virus (100-300
focus forming units/well) and incubated for 1hr at 37 ⁰C. Also included in this
mixture to neutralize any potential VSV-G carryover virus was 1E9F9, a mouse
anti-VSV Indiana G, at a concentration of 600 ng/ml (Absolute Antibody,
Ab01402-2.0). The serum-virus mixture was then used to replace the media on
VeroE6 TMPRSS2 cells. 22 hours post infection, the cells were washed and fixed
with 4% paraformaldehyde before visualization on an S6 FluoroSpot Analyzer
(CTL, Shaker Heights OH). Individual infected foci were enumerated, and the
values compared to control wells without antibody. The focus reduction
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neutralization titer 50% (FRNT50) was measured as the greatest serum dilution at
which focus count was reduced by at least 50% relative to control cells that were
infected with pseudotype virus in the absence of human serum. FRNT50 titers for
each sample were measured in at least two technical replicates and were
reported for each sample as the geometric mean.

ELISA
Flat bottom, high binding polystyrene 96-well plates (Corning, 9018) were coated
overnight at 4oC with either 2 ug/ml SARS-CoV-2 Spike Protein ECD (Sino
Biological, 40589-V08B1) or 1 ug/ml SARS-CoV-2 Spike-RBD (Sino Biological,
40592-V08B-B) in PBS. The following day the coating buffer was aspirated, and
the plate was washed with PBST and then dried. Once dried the plate was
blocked with PBS + 1% BSA for 2 hr at RT before heat-inactivated serum
samples diluted in PBS + 1% BSA were added for 1 hour at room temperature.
The ELISA plate was then washed 4 times with PBS + 0.05% Tween-20 (PBST),
followed by addition of 100 uL of 1:2000 goat anti-mouse IgG-ALP (Abcam,
ab97020) diluted in PBST + 1% BSA. After 1 hour at room temperature, plates
were washed 4 times with PBST and then developed with PNPP (Thermo,
37621) for 30 minutes at room temperature. Optical density (OD) was measured
at 405 nm. Endpoint titers were calculated as the highest reciprocal dilution that
emitted an optical density exceeding 3x secondary antibody only control.
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Mouse ELISpots
Mouse IL-2 (MABTECH, 3441-4APW-2), IL-4 (MABTECH, 3311-4APW-2), and
IL-10 (MABTECH, 3432-4APW-2) ELISpotPLUS plates as well as Mouse IFN
ELISpotPRO plates (MABTECH, 3421M-2AST-2) were washed with PBS and
blocked overnight at 4oC in RPMI 1640 media (Invitrogen, 11875085) + 10 %
FBS (Life Technologies, 16000044) + Antibiotic-Antimycotic (Invitrogen,
15240062) + GlutaMAX (Invitrogen, 35050061) (RPMI10+ media). The next day,
spleens were processed into single cell suspensions in PBS and then spun at
1500g for 10 min. Red blood cells were lysed with ACK lysis buffer (Quality
Biological Inc., 118-156-721EA) + 1:500 benzonase (Sigma, E1014-25KU) for 10
minutes at RT. Splenocytes were plated in RPMI10+ media at 2E5 cells per well
and stimulated for 20 hrs (37°C, 5% CO2) with peptide pools of 15-mers with 11
amino acid overlap covering either the S1 or S2 fragment of either WA1 SARSCoV-2 spike protein (JPT, PM-WCPV-S-1) or B.1.1.7/alpha variant spike protein
(JPT, PM-SARS2-SMUT01-1) at a final concentration of 5 ug/ml. PMA/Ionomycin
was used as a positive control (eBioscience, 00-4970-03) for all murine ELISpots
and RPMI10+ media alone was used as a negative control for each animal.
Plates were then incubated in ddH2O for 2 minutes and then washed 5x with
PBS before incubating with biotinylated anti-cytokine antibody at the
manufacture’s recommended concentration in PBS + 1% BSA for 2 hr at RT.
Following another 5x PBS wash plates were incubated with Streptavidin-ALP in
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PBS + 1% BSA for 1 hr at RT and then 5x washed again with PBS. Nitor-blue
Tetrazolium Chloride/5-bromo-4-chloro 3 ‘indolyl phosphate p-toludine salt
(NBT/BCIP chromagen) substrate solution was added after the final wash for 1012 min to allow spots to form. Spots were quantified on a CTL ImmunoSpot S6
Core Analyzer.

Macaques.
All procedures were approved by the Institutional Animal Care and Use
Committee of the Children’s Hospital of Philadelphia (CHOP). Animals were
negative for viral pathogens including SIV (simian immunodeficiency virus), STLV
(simian-T-lymphotrophic virus), SRV (simian retrovirus), and B virus (herpesvirus
1) and housed in an AAALAC-accredited facility at CHOP on a 12-hour timed
light/dark cycle. Animals received varied enrichment including food treats,
manipulatives, visual and auditory stimuli, and social interactions throughout the
study. Four 2-3yo female cynomolgus monkeys (Macaca fascicularis) were
treated with the clinical candidates intramuscularly at doses of 1E11 or 1E12
gc/animal. Serum and PBMC samples were obtained at baseline and 2-week
intervals for analyses of immunogenicity. At necropsy, splenocytes, popliteal and
inguinal lymph nodes and exposed and unexposed skeletal muscle were
harvested for immunologic and histopathologic studies.
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Macaque Immunohistochemistry
Skeletal muscle harvested at necropsy was embedded in O.C.T. (Tissue-Tek,
4583) within 7x7x5 mm base molds (Richard-Allan Scientific, 58949) by rapid
submersion in liquid nitrogen-cooled isopentane. All steps with tissue sectioning
and IHC are the same as with mouse tissue through blocking in 10% normal
donkey serum (Abcam, ab7475) for 20 minutes at RT. After blocking, slides were
incubated in PBS with rat anti-CD8 (Bio-Rad, YTC182.20) plus either rabbit
polyclonal anti-SARS-CoV-2 Spike/RBD (Sino, 40592-T62) or rabbit polyclonal
anti-CD11b (Abcam, ab52478) for 1 hour at 37oC. Slides were then washed 3x10
minutes in PBS at RT and again blocked with 10% normal donkey serum
(Abcam, ab7475) for 20 minutes at room temperature before being incubated
with PBS containing WGA-555 (Thermo Fisher, W32464), donkey anti-rabbitAF488 (Abcam, ab150061), and donkey anti-rat-AF647 (Abcam, ab150155) for
30 minutes at 37oC. Following another 3x10 min washes in PBS, slides were
mounted in VECTASHIELD mounting media containing DAPI (Vector
Laboratories, H-1500). Images were taken using a Zeiss Observer 7 widefield
microscope (Zeiss).

Macaque ELISpot
Monkey IFNγ ELISpotPRO plates (MABTECH, 3421M-2AST-2) were washed
with PBS and blocked overnight at 4oC in RPMI10+ media. 2E5 macaque
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PBMCs were plated in RPMI10+ media and stimulated for 24 hrs (37°C, 5%
CO2) with peptide pools of 15-mers with 11 amino acid overlap covering either
the S1 or S2 fragment of WA1 SARS-CoV-2 spike protein (JPT, PM-WCPV-S-1)
at a final concentration of 5 ug/ml. PMA/Ionomycin was used as a positive control
(eBioscience, 00-4970-03) and RPMI10+ media alone was used as a negative
control for each animal. Plates were then incubated in ddH2O for 2 minutes and
then washed 5x with PBS before incubating with ALP-conjugated anti-IFNg
antibody at the manufacture’s recommended concentration in PBS + 1% BSA for
2 hr at RT. Following 5x washes in PBS NBT/BCIP chromagen substrate solution
was added for 15 min to allow spots to form. Spots were quantified on a CTL
ImmunoSpot S6 Core Analyzer.

Statical Analysis
Data visualization and statistical analysis was performed using GraphPad Prism
Version 9.1.0. Comparisons between multiple groups were compared by either
Brown–Forsythe and Welch’s analysis of variance (ANOVA) followed by
Dunnett’s T3 multiple comparisons test or Kruskal–Wallis analysis of variance
(ANOVA) followed by Dunn’s multiple comparisons test. Welch’s t-test was used
to compare two groups. Statistical significance was considered when P values
were <0.05.

93

CHAPTER 4: Conclusions and Future Directions
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4.1 Summary of findings
AAV is an ideal vector for gene transfer in vivo. However, the limited DNA
packaging capacity of AAV and the episomal nature of the AAV genome can
pose challenges for use of AAV as a gene therapy vector in certain contexts such
as the transfer of large genes or the transfer of genes to cells that will later
divide, respectively. Additionally, the magnitude of potential immunogenicity
against exogenous AAV-delivered transgene products isn’t fully understood. This
dissertation consists of two in vivo AAV-mediated gene transfer projects that
utilized engineered, miniaturized versions of larger genes to overcome the
packaging capacity of AAV to achieve disparate outcomes. While the first project
develops a structurally optimized nano4-Utrophin to maximize therapeutic
efficacy while avoiding transgene immunogenicity for Duchene muscular
dystrophy gene therapy, the second project demonstrates that exogenous
transgene immunogenicity against AAV delivered SARS-CoV-2 spike protein
functions as a highly effective, T cell predominant vaccine for SARS-CoV-2.
Chapter 1 discussed AAV as a gene therapy vector, particularly in the
context of Duchenne muscular dystrophy. I reviewed the Stedman’s lab’s work
demonstrating the efficacy of AAV9-µUtrophin in the mdx mouse model of DMD
as well as the non-immunogenicity of AAV9-µUtrophin in the German shorthaired
pointer muscular dystrophy model (GSHPMD) canine model. This chapter also
introduced my observation of µUtrophin fragmentation at the internal deletion site
introduced to truncate the size of utrophin to fit within the DNA packaging
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capacity of AAV (Fig. 1.4). I then discussed how this fragmentation of µUtrophin
could threaten the durability of these AAV-based gene therapies for Duchenne
muscular dystrophy as episomal AAV genomes are lost from proliferating
myoblasts during muscle regeneration, leading to a reduction in the percentage
of transduced/treated myonuclei post regeneration.
In chapter 2, I reconstructed the evolution of striated muscle and
determined that the evolution of muscle correlates with the emergence of the
protein titin, but not dystrophin. We determined that full-length dystrophin and all
component members of the dystrophin-associated protein complex evolved prior
to the evolution of striated muscle. We found that modern day dystrophin arose
from the fusion of two previously existing, independent genes: 1) an MACF1
ortholog encoding an N-terminal ABD and a rod domain of spectrin repeats, and
2) a C-terminal dystrophin ortholog consisting of just the b-dystroglycan binding
CRR and CTR domains of dystrophin. Based on this evolutionary reconstruction
of dystrophin’s origin, we proposed a structural model for how the spectrin
repeats within the rod domain of dystrophin and utrophin interact/overlap to form
a continuous, interlocking structure. Using this structural model of the
dystrophin/utrophin rod domain, we engineered a new AAV-deliverable utrophinbased transgene (nano4-Utrophin) that has a chimeric spectrin repeat to
maintain tensile strength along the entire truncated rod domain. I then showed
that following systemic administration using AAV9, nano4-Utrophin can correct
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the dystrophic phenotype in mdx mice without generating a cleavage fragment
like that observed following treatment with AAV9-µUtrophin.
Chapter 3 builds directly off the observation described in chapter 1 that
AAV-µDystrophin is immunogenic following intramuscular injection in the
GSHPMD canine model of DMD. In response to the COVID pandemic we
created miniaturized, AAV-deliverable spike transgenes and demonstrated that
intramuscular injection of AAV-spike resulted in a robust cellular immune
response against spike expressing muscle fibers at the site of injection in both
mice and macaques. Surprisingly, despite eliciting a strong systemic T cell
response to spike peptides, the AAV-spike vaccines failed to induce neutralizing
antibodies in either mice or macaques. I then demonstrated that AAV-spike
vaccination protected humanized hACE2 transgenic mice from subsequent lethal
SARS-CoV-2 challenge. This protection was associated with prevention of viral
pneumonia and weight loss in vaccinated mice post SARS-CoV-2 infection as
well as reduced viral mRNA and protein in the lungs post infection. This work is
the first to demonstrate that AAV6 and AAV9 can function as effective vaccine
vectors. Overall, this work highlights the potential risk of immunogenicity against
AAV-delivered exogenous transgenes as well as demonstrates that vaccines can
provide efficacy even in the absence of neutralizing antibodies.
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4.2 Evolution of Skeletal Muscle
4.2.1 Evolution of Titin and Skeletal Muscle
Vertebrate titins serve in monomeric form as the primary scaffold for
sarcomere formation by linking the Z-disc to the thick filament (Chopra et al.,
2018; Tonino et al., 2017; Tskhovrebova and Trinick, 2003; Zoghbi et al., 2008).
However, titin homologs in invertebrates are widely divergent in number, primary
structure, domain composition, and length, complicating the ability to delineate
their evolutionary relationship to vertebrate titins (Tskhovrebova and Trinick,
2003). We identified a conserved N-terminal spectrin repeat containing region on
invertebrate titins that is no longer expressed with vertebrate titins but remains
immediately upstream in vertebrate genomes as independently expressed
genes. Despite no longer being expressed as part titin in vertebrates, this
conserved ancestral N-terminal spectrin repeat region continues to be expressed
as part of titin in many invertebrates, allowing us to clearly identify titin orthologs.
Cnidarians are the earliest branching multicellular eukaryotic lineage with
sarcomeric muscle, and we show that titin orthologs are present and expressed
at the mRNA level in three classes of cnidarians. While the inability to identify titin
or other sarcomeric proteins lead others to conclude that striated muscle
independently evolved in cnidarians and all other eukaryotic lineages with
bilateral symmetry (Steinmetz et al., 2012), the presence of this highly conserved
N-terminal region of the ancestral titin gene on a titin-like protein allowed us to
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identify its orthology. As this is the only protein whose emergence correlates with
the emergence of sarcomeric muscle, this suggests that the scaffolding function
of titin was likely the critical evolutionary event that facilitated the emergence of
sarcomeric muscle.
Further studies are needed to confirm the function of this putative titin
ortholog in cnidarian muscle. While the current genetic intractability of cnidarians
makes genetic knockout or GFP tagging of the protein impossible,
immunohistochemistry could be done to confirm the protein localizes to
sarcomeres. Alternatively, native actomyosin from the striated myoepithelium of
adult jellyfish can be isolated and the proteins present can be analyzed by mass
spectrometry to confirm the presence of the titin ortholog in the sarcomere
(Tanaka et al., 2018).

4.3 Engineering a Structurally Optimized, AAV-Deliverable Utrophin Protein
4.3.1 Evolution of Dystrophin and the “Interlocking Chain” Structural Model of the
Dystrophin Rod Domain
While evolution of titin correlates with the emergence of striated,
sarcomeric muscle, we show that all the members of membrane spanning
dystrophin-associated protein complex and an ancestral dystrophin ortholog
consisting of just the C-terminal b-dystroglycan binding CRR and CTR domains
of human dystrophin emerged far earlier than muscle in unicellular eukaryotes.
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To investigate the emergence of the dystrophin rod domain, we identified a
conserved phase 0 intron at HMM position 46 within almost every spectrin repeat
of human dystrophin. This HMM position 46 phase 0 intron is conserved in the
dystrophin ortholog of every species with full-length dystrophin. We show that
species that diverged just prior to the emergence of modern full-length dystrophin
have an MACF1 ortholog with an N-terminal actin-binding domain connected to
many spectrin repeats with a conserved phase 0 intron at HMM position 46 (the
human MACF1 protein similarly has these conserved phase 0 introns). As intron
position and phase evolve slower than amino acid sequence, these gene
structures provide evidence that full-length dystrophin arose when a partial gene
duplication of the ancestral MACF1 ortholog encoding the N-terminal actin
binding domain and 24 spectrin repeats became linked in cis to the gene
encoding the ancestral C-terminal dystrophin ortholog.
Using dystrophin’s evolutionary relationship to MACF1 and the
spectroplakin protein family, we modeled spectrin repeats from the dystrophin
rod domain using plectin (an MACF1 paralog) as the homology model template
(Ortega et al., 2016). The resulting structure reveled significant overlap and
interaction between adjacent spectrin repeats (Fig. 2.7C), unlike when the
evolutionarily unrelated protein spectrin was used as the homology model
template (Fig. 2.7B). Based on these models we proposed an “interlocking
chain” structural model for how the spectrin repeats within the rod domain of
dystrophin and utrophin interact/overlap to form a continuous, interlocking
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structure. Under this structural model, amino acid interactions between adjacent
repeats would have co-evolved (Marks et al., 2012) to maintain tensile strength
across the “interlocking” triple helical spectrin repeats of the dystrophin rod
domain to aid in longitudinal force transmission. Under these circumstances,
there would be negative evolutionary pressure against the novel juxtaposition of
non-adjacent spectrin repeats by internal gene deletion or duplication. This
mechanism potentially explains both why there is weak correlation between the
size of in frame rod domain deletions and disease severity in Becker muscular
dystrophy patients (Matsumura et al., 1993; Taglia et al., 2015) as well as the
potential mechanism behind Becker muscular dystrophy patients with partial rod
domain duplications (Angelini et al., 1990; Miao et al., 2016).

4.3.2 AAV-nano4-Utrophin Complements for Absence of Dystrophin in Mdx Mice
Building of this evolutionarily informed structural model of the dystrophin,
and therefore utrophin, rod domain, we engineered a second generation AAVdeliverable nano4-Utrophin protein with a chimeric spectrin repeat to preserve all
the native interactions between naturally adjacent spectrin repeats (Fig. 2.8A).
Therefore, nano4-Utrophin should maintain tensile strength along the entire
truncated rod domain. Following systemic neonatal injection of mdx mice with
AAV9, nano4-Utrophin localizes to the sarcolemmal membrane, restores
sarcolemmal localization of the dystrophin-associated protein complex member g101

Sarcoglycan, and prevents ongoing muscle regeneration. Importantly, all of this
occurs in without the generating a cleavage fragment like that observed following
treatment with the first generation AAV9-µUtrophin (Fig. 2.8C). This suggests
AAV9-nano4-Utrophin may be a more effective and durable therapy that AAV9µUtrophin.
To directly compare the relative durability of AAV9-µUtrophin and AAV9n4-Utrophin in the future, we will IP inject three cohorts of mdx mice neonatally
with either 1E14 vg/kg of AAV9-µUtrophin, AAV9-nano4-Utrophin, or PBS as a
negative control. One year post treatment, the skeletal muscles and heart will be
harvested and assessed for comparative level of transgene expression. I have
observed that µUtrophin expression decreases significantly by 1 year, so if
nano4-Utrophin is more durable it should remain present at higher levels. The
comparative efficacy of AAV9-µUtrophin and AAV9-n4-Utrophin can be
determined by performing assays such as Evan’s blue dye uptake following
forced eccentric skeletal muscle contraction or cardiac challenge with
isoproterenol, % force drop following eccentric skeletal muscle contraction,
and/or maximal isometric force generation.
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4.4 AAV-Spike Protects hACE2 Mice from Lethal SARS-CoV-2 Infection
4.4.1 AAV-Spike Induces T Cell Predominant Immunity in Mice and Macaques
In response to the COVID pandemic and our observations that AAV9-
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Fig. 4.1 SARS-CoV-2 spike protein with M8/M8B deletion mapped. Each
protomer of the SARS-CoV-2 spike protein homotrimer (PDB structure 6VXX)
has been colored a different color and each N-terminal domain (NTD) that has
been deleted (DNTD) has been colored black.
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Following intramuscular injection of AAV9-M8 or -M8B in both mice and
macaques we observed macrophage and CD8+ T cell infiltration at the site of
injection 3-4 weeks post injection. This coincided with detection of systemic T cell
response against spike peptide epitopes detected by ELISpot in both species.
This indicates that in both species, AAV-spike is eliciting a robust cell mediated
immune response against spike and this is resulting in immune infiltration at the
site of injection targeting the spike being expressed from the AAV transduced
muscle fibers. Interestingly, unlike mRNA vaccines which only express spike
antigens for up to a few days, such prolonged antigen expression by AAV vectors
may forgo any need for boosters as we detected spike expression in muscle
fibers up to 6 weeks post vaccination.
Serological analysis revealed that while both mice and macaques
generated low levels of non-neutralizing antibodies against spike in response to
AAV vaccination, neither species generated quantifiable neutralizing antibodies
post vaccination. Together, this shows that the immune response to AAV-spike in
both mice and macaques is characterized by a strong T cell response with little to
no neutralizing antibody production.

4.4.2 AAV-Spike Protects hACE2 mice from Lethal SARS-CoV-2 Infection
As it is widely assumed that vaccine efficacy is tightly linked to titers of
measurable neutralizing antibodies (Erasmus et al., 2020; Sanchez-Felipe et al.,
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2021), we weren’t sure if the AAV-spike induced immune response would
function as an effective vaccine. However, we found that humanized k18-hACE2
mice were almost completely protected against lethal SARS-CoV-2 challenge
and pneumonia following vaccination with either AAV6-M8B, AAV9-M8, or AAV9M8B. After being infected with a dose of SARS-CoV-2 that was lethal in >90% of
unvaccinated mice, vaccinated mice demonstrated no clinical symptoms of
illness and were protected from weight loss and pneumonia post infection. This
immunity was additionally long lived, with one vaccinated cohort of mice
demonstrating efficacy at 4.5 months post. Furthermore, we found that AAVspike remains effective even after months of standard refrigeration. Combined
with the demonstrated long-term efficacy following single dose administration,
these features make the vaccine platform potentially advantageous for
distribution to rural, sparsely populated, or resource-limited areas.

4.4 Concluding Remarks
Overall, this work provides a better understanding of the immune
response to AAV delivered exogenous transgenes and demonstrates AAV is an
effective platform for both treating Duchenne muscular dystrophy and functioning
as a COVID vaccine. The major insight from both the µUtrophin and the nano4Utrophin work is that molecular evolution can lead to unexpected therapeutic
insights. The paralogous nature of utrophin allows it to compensate for the
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function of dystrophin without being immunogenic in dystrophin null patients.
Additionally, reconstructing the molecular evolution of dystrophin resulted in a
structural model of the rod domain that we believe will allow for the generation of
fully functionally, 1/3 size utrophin (and dystrophin) proteins. The major insight
from the vaccine work is that AAV delivered transgenes aren’t only capable of
eliciting an immune response, that immune response can protect mice from an
otherwise lethal SARS-CoV-2 infection all without inducing neutralizing
antibodies. The insights from this work can be used to develop T cell exclusive
vaccines in the future.
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